Document:

Exhibit 10.1

 

SECURITIES
PURCHASE AGREEMENT

 

This
SECURITIES PURCHASE AGREEMENT (this “Agreement”), dated as of December 18, 2020, is by and among Cyclacel
Pharmaceuticals, Inc., a Delaware corporation with headquarters located at 200 Connell Drive, Suite 1500, Berkeley Heights, New
Jersey 07922 (the “Company”), and Acorn Bioventures, L.P., a Delaware limited partnership (the “Buyer”).

 

RECITALS

 

A.       The
Buyer wishes to purchase, and the Company wishes to sell, upon the terms and subject conditions stated in this Agreement, an aggregate
of (i) 485,912 shares of Common Stock (as defined herein) (the “Common Shares”) pursuant to the Company’s
shelf registration statement on Form S-3 (Registration Number 333-231923) (the “Registration Statement”), which
has been declared effective in accordance with the Securities Act of 1933, as amended (the “1933 Act”), by the
United States Securities and Exchange Commission (the “SEC”), (ii) 237,745 shares of Series B Convertible Preferred
Stock (the “Series B Stock”) convertible into 1,188,725 shares of Common Stock, at a conversion price of $4.18
per share (the “Series B Preferred Shares” and together with the Series B Stock, the “Series B Securities”),
pursuant to the Registration Statement, and (iii) a Warrant, in the form attached hereto as Exhibit A (the “Warrants”),
to initially purchase an aggregate of up to 669,854 shares of Common Stock (the “Warrant Shares” and together
with the Warrant, the “Warrant Securities”), at an exercise price of $4.13 per share, in reliance upon the exemption
from securities registration afforded by Section 4(a)(2) of the 1933 Act, and Rule 506(b) of Regulation D (“Regulation
D”) as promulgated by the SEC under the 1933 Act.

 

B.       The
Common Shares, the Series B Stock, the Series B Preferred Shares, the Warrants and the Warrant Shares are collectively referred
to herein as the “Securities”.

 

AGREEMENT

 

NOW,
THEREFORE, in consideration of the premises and the mutual covenants contained herein and for other good and valuable consideration,
the receipt and sufficiency of which are hereby acknowledged, the Company and the Buyer hereby agree as follows:

 

1.                 
PURCHASE AND SALE OF COMMON SHARES, SERIES B STOCK AND WARRANTS.

 

a.                  
Purchase of Common Shares, Series B Stock and Warrants. Subject to the satisfaction (or waiver) of the conditions
set forth in Sections 6 and 7 below, the Company shall issue and sell to the Buyer, and the Buyer agree to purchase from the Company
on the Closing Date (as defined below), (i) 485,912 Common Shares, (ii) 237,745 shares of Series B Stock convertible into 1,188,725
Series B Preferred Shares and (iii) the Warrants to initially acquire an aggregate of up to 669,854 Warrant Shares.

 

    

     

    

 

b.                  Closing.
The closing (the “Closing”) of the purchase of the Common Shares, the Series B Stock and the Warrants by
the Buyer shall occur at the offices of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C., 666
Third Avenue, New York, NY 10017. The date and time of the Closing (the “Closing Date”) shall be 10:00
a.m., New York time, on the first (1st) Business Day (as defined below) on which the conditions to the Closing set forth in
Sections 6 and 7 below are satisfied or waived (or such other date as is mutually agreed to by the Company and the Buyer). As
used herein “Business Day” means any day other than a Saturday, Sunday or other day on which commercial
banks in New York, New York are authorized or required by law to remain closed.

 

c.                  
Purchase Price. The aggregate gross purchase price for the Common Shares, the Series B Stock and the Warrants to be purchased by the Buyer
hereunder shall be $6,999,982.65 (the “Purchase Price”).

 

d.                 
Form of Payment; Deliveries. On the Closing Date, (i) the Buyer shall pay the Purchase Price (less the amount withheld
pursuant to Section 4(g)) to the Company for the Common Shares, the Series B Stock and the Warrants to be issued and sold to the
Buyer at the Closing, by wire transfer of immediately available funds in accordance with the Flow of Funds Letter (as defined below)
and (ii) the Company shall (A) cause American Stock Transfer & Trust Company (together with any subsequent transfer agent,
the “Transfer Agent”) through the Depository Trust Company (“DTC”) Fast Automated Securities
Transfer Program, to credit such number of Common Shares as set forth on the signature page hereto for the Buyer’s or its
designee’s balance account with DTC through its Deposit/Withdrawal at Custodian system, (B) deliver to the Buyer such number
of shares of Series B Stock as set forth on the signature page hereto and (C) deliver to the Buyer the Warrants pursuant to which
the Buyer shall have the right to initially acquire such number of Warrant Shares as set forth on the signature page hereto, duly
executed on behalf of the Company and registered in the name of the Buyer or its designee.

 

2.                 
BUYER’S REPRESENTATIONS AND WARRANTIES.

 

The
Buyer represents and warrants to the Company that, as of the date hereof and as of the Closing Date:

 

a.                  
Organization; Authority. The Buyer is an entity duly organized, validly existing and in good standing under the laws
of the jurisdiction of its organization with the requisite power and authority to enter into and to consummate the transactions
contemplated by this Agreement and otherwise to carry out its obligations hereunder.

 

b.                 
Validity; Enforcement. This Agreement has been duly and validly authorized, executed and delivered on behalf of the
Buyer and shall constitute the legal, valid and binding obligations of the Buyer enforceable against the Buyer in accordance with
its terms, except as such enforceability may be limited by general principles of equity or to applicable bankruptcy, insolvency,
reorganization, moratorium, liquidation and other similar laws relating to, or affecting generally, the enforcement of applicable
creditors’ rights and remedies.

 

c.                   No
Public Sale or Distribution of Warrant Securities. The Buyer is acquiring the Warrant Securities for its own account and
not with a view towards, or for resale in connection with, the public sale or distribution thereof in violation of applicable
securities laws, except pursuant to sales registered or exempted under the 1933 Act; provided, however, by making the
representations herein, the Buyer does not agree, or make any representation or warranty, to hold any of the Securities for
any minimum or other specific term and reserves the right to dispose of the Securities at any time in accordance with or
pursuant to a registration statement or an exemption under the 1933 Act. The Buyer is acquiring the Securities hereunder in
the ordinary course of its business. The Buyer does not presently have any agreement or understanding, directly or
indirectly, with any Person to distribute any of the Securities in violation of applicable securities laws.

 

    -2- 

     

    

 

d.                 
Accredited Investor Status. At the time the Buyer was offered the Securities, it was, and as of the date hereof it
is, an “accredited investor” as defined in Rule 501(a)(1), (a)(2), (a)(3), (a)(7) or (a)(8) under the 1933 Act.

 

e.                  
Experience of Buyer. The Buyer, either alone or together with its representatives, has such knowledge, sophistication
and experience in business and financial matters so as to be capable of evaluating the merits and risks of the prospective investment
in the Securities, and has so evaluated the merits and risks of such investment. The Buyer is able to bear the economic risk of
an investment in the Securities and, at the present time, is able to afford a complete loss of such investment.

 

f.                   Reliance on Exemptions. The Buyer understands that the Warrant Securities are being offered and sold to it in reliance
on specific exemptions from the registration requirements of United States federal and state securities laws and that the Company
is relying in part upon the truth and accuracy of, and the Buyer’s compliance with, the representations, warranties, agreements,
acknowledgments and understandings of the Buyer set forth herein in order to determine the availability of such exemptions and
the eligibility of such Buyer to acquire the Securities.

 

g.                 
Information. The Buyer and its advisors, if any, have been furnished with all materials relating to the business,
finances and operations of the Company and materials relating to the offer and sale of the Securities which have been requested
by the Buyer. The Buyer and its advisors, if any, have been afforded the opportunity to ask questions of the Company. Neither such
inquiries nor any other due diligence investigations conducted by the Buyer or its advisors, if any, or its representatives shall
modify, amend or affect the Buyer’s right to rely on the Company’s representations and warranties contained herein
or any representations and warranties contained in any other Transaction Document or any other document or instrument executed
and/or delivered in connection with this Agreement or the consummation of the transaction contemplated hereby. The Buyer has sought
such accounting, legal and tax advice as it has considered necessary to make an informed investment decision with respect to its
acquisition of the Securities.

 

h.                 
No Governmental Review. The Buyer understands that no United States federal or state agency or any other government
or governmental agency has passed on or made any recommendation or endorsement of the Securities or the fairness or suitability
of the investment in the Securities nor have such authorities passed upon or endorsed the merits of the offering of the Securities.

 

    -3- 

     

    

 

i.                    Transfer
or Resale. The Buyer understands that except as provided herein: (i) the Warrant Securities have not been and are not
being registered under the 1933 Act or any state securities laws, and may not be offered for sale, sold, assigned or
transferred unless (A) subsequently registered thereunder, (B) the Buyer shall have delivered to the Company (if requested by
the Company) an opinion of counsel to the Buyer, in a form reasonably acceptable to the Company, to the effect that the
Warrants or the Warrant Shares to be sold, assigned or transferred may be sold, assigned or transferred pursuant to an
exemption from such registration, or (C) the Buyer provides the Company with reasonable assurance that the Warrants or
Warrant Shares can be sold, assigned or transferred pursuant to Rule 144 or Rule 144A promulgated under the 1933 Act (or a
successor rule thereto) (collectively, “Rule 144”); (ii) any sale of the Warrants or Warrant Shares made
in reliance on Rule 144 may be made only in accordance with the terms of Rule 144, and further, if Rule 144 is not
applicable, any resale of the Warrants or Warrant Shares under circumstances in which the seller (or the Person (as defined
below) through whom the sale is made) may be deemed to be an underwriter (as that term is defined in the 1933 Act) may
require compliance with some other exemption under the 1933 Act or the rules and regulations of the SEC promulgated
thereunder; and (iii) neither the Company nor any other Person is under any obligation to register the Warrants or Warrant
Shares under the 1933 Act or any state securities laws or to comply with the terms and conditions of any exemption
thereunder.

 

j.                   
Certain Trading Activities. The Buyer represents and warrants to the Company that at no time prior to the date of
this Agreement has any of the Buyer, its agents, representatives or affiliates engaged in or effected, in any manner whatsoever,
directly or indirectly, any (i) “short sale” (as such term is defined in Rule 200 of Regulation SHO of the Securities
Exchange Act of 1934, as amended (the “1934 Act”)) of the Common Stock or (ii) hedging transaction, which establishes
a net short position with respect to the Common Stock.

 

k.                 
General Solicitation. The Buyer is not purchasing the Warrant Securities as a result of any advertisement, article,
notice or other communication regarding the Securities published in any newspaper, magazine or similar media or broadcast over
television or radio or presented at any seminar.

 

l.                   
Manipulation of Price. Since the time that such Buyer was first contacted by the Company or its agent regarding the
investment in the Company contemplated herein, the Buyer has not, and, to the knowledge of the Buyer, no Person acting on its behalf
has, directly or indirectly, (i) taken any action designed to cause or to result in the stabilization or manipulation of the price
of any security of the Company to facilitate the sale or resale of any of the Securities, (ii) sold, bid for, purchased, or paid
any compensation for soliciting purchases of, any of the Securities, or (iii) paid or agreed to pay to any Person any compensation
for soliciting another to purchase any other securities of the Company.

 

    -4- 

     

    

 

3.                 
REPRESENTATIONS AND WARRANTIES OF THE COMPANY.

 

The
Company represents and warrants to the Buyer that, as of the date hereof and as of the Closing Date:

 

a.                   Organization
and Qualification. Each of the Company and each of its Subsidiaries are entities duly organized and validly existing and
in good standing under the laws of the jurisdiction in which they are formed, and have the requisite power and authority to
own their properties and to carry on their business as now being conducted and as presently proposed to be conducted. Each of
the Company and each of its Subsidiaries is duly qualified as a foreign entity to do business and is in good standing in
every jurisdiction in which its ownership of property or the nature of the business conducted by it makes such qualification
necessary, except to the extent that the failure to be so qualified or be in good standing would not reasonably be expected
to have a Material Adverse Effect (as defined below). As used in this Agreement, “Material Adverse Effect”
means any material adverse effect on (i) the business, properties, assets, liabilities, operations (including results
thereof), condition (financial or otherwise) or prospects of the Company or any Subsidiary, individually or taken as a whole,
(ii) the transactions contemplated hereby or in any of the other Transaction Documents or any other agreements or instruments
to be entered into in connection herewith or therewith or (iii) the authority or ability of the Company to perform any of
their respective obligations under any of the Transaction Documents (as defined below). All of the direct and indirect
Subsidiaries of the Company are set forth in the SEC Documents. The Company owns, directly or indirectly, all of the capital
stock or other equity interests of each Subsidiary free and clear of any Liens, and all of the issued and outstanding shares
of capital stock of each Subsidiary are validly issued and are fully paid, non-assessable and free of preemptive and similar
rights to subscribe for or purchase securities. If the Company has no Subsidiaries, all other references to the Subsidiaries
or any of them in the Transaction Documents shall be disregarded. “Subsidiaries” means any Person in which
the Company, directly or indirectly, (A) owns any of the outstanding capital stock or holds any equity or similar interest of
such Person or (B) controls or operates all or any part of the business, operations or administration of such Person, and
each of the foregoing, is individually referred to herein as a “Subsidiary”.

 

b.                  Authorization;
Enforcement; Validity. The Company has the requisite power and authority to enter into and perform its obligations under
this Agreement and the other Transaction Documents and to issue the Securities in accordance with the terms hereof and
thereof. The execution and delivery of this Agreement and the other Transaction Documents by the Company and the consummation
by the Company of the transactions contemplated hereby and thereby (including, without limitation, the offer and sale of the
Common Shares and the offer and sale of the Series B Securities and the Warrant Securities and the reservation for issuance
and issuance of the Series B Preferred Shares issuable upon conversion of the Series B Stock and the Warrant Shares issuable
upon exercise of the Warrants) have been duly authorized by the Company’s board of directors and (other than (i) the
filing with the SEC of the prospectus supplement relating to the offer and sale of the Common Shares and the Series B Stock
pursuant to Rule 424(b) under the 1933 Act (the “Prospectus Supplement”) supplementing the base prospectus
forming part of the Registration Statement (the “Prospectus”), (ii) the filing of a Form D with the SEC
relating to the offer and sale of the Warrant Securities pursuant to Regulation D, (iii) the filing of a Notice of Additional
Listing with The Nasdaq Capital Market (the “Principal Market”) and (iv) any other filings as may be
required by any state securities authorities), no further filing, consent or authorization is required by the Company, its
board of directors or its stockholders or other governing body. This Agreement has been, and the other Transaction Documents
will be prior to the Closing, duly executed and delivered by the Company, and each constitutes the legal, valid and binding
obligations of the Company, enforceable against the Company in accordance with its respective terms, except as such
enforceability may be limited by general principles of equity or applicable bankruptcy, insolvency, reorganization,
moratorium, liquidation or similar laws relating to, or affecting generally, the enforcement of applicable creditors’
rights and remedies and except as rights to indemnification and to contribution may be limited by federal or state securities
law. “Transaction Documents” means, collectively, this Agreement, the Certificate of Designations of the
Series B Stock, and the Warrants, and each of the other agreements and instruments entered into or delivered by any of the
parties hereto in connection with the transactions contemplated hereby and thereby, as may be amended from time to time.

 

    -5- 

     

    

 

c.                   Issuance
of Securities; Registration Statement. The issuance of the Common Shares, the Series B Stock and the Warrants are duly
authorized and, upon issuance and payment in accordance with the terms of the Transaction Documents shall be validly issued,
fully paid and non-assessable and free from all preemptive or similar rights, mortgages, defects, claims, liens, pledges,
charges, taxes, rights of first refusal, encumbrances, security interests and other encumbrances (collectively
“Liens”) with respect to the issuance thereof. As of the Closing, the Company shall have reserved from its
duly authorized capital stock not less than 100% of the maximum number of shares of Common Stock issuable upon conversion of
the Series B Stock and the exercise of the Warrants (without taking into account any limitations on the conversion of the
Series B Stock and the exercise of the Warrants set forth in the Warrants). Upon conversion in accordance with the terms of
the Certificate of Designation of the Series B Stock, the Series B Preferred Shares, when issued, will be validly issued,
fully paid and nonassessable and free from all preemptive or similar rights or Liens with respect to the issue thereof, with
the holders being entitled to all rights accorded to a holder of Common Stock. Upon exercise in accordance with the terms of
the Warrants, the Warrant Shares, when issued, will be validly issued, fully paid and nonassessable and free from all
preemptive or similar rights or Liens with respect to the issue thereof, with the holders being entitled to all rights
accorded to a holder of Common Stock. Upon receipt of the Common Shares, the Series B Stock and the Warrants at the Closing
and upon receipt of Series B Preferred Shares and the Warrant Shares upon conversion of the Series B Stock and exercise of
the Warrants, respectively, the Buyer will have good and marketable title to such Common Shares, Series B Stock, Series B
Preferred Shares, Warrants, and Warrant Shares, respectively. Subject to the accuracy of the representations and warranties
of the Buyer in this Agreement, the offer and sale of the Warrant Securities to the Buyer under this Agreement are exempt
from registration under the 1933 Act under Section 4(a)(2) of the 1933 Act and Rule 506(b) of Regulation D. The offer and
sale of all of the Common Shares and the Series B Securities to the Buyer under this Agreement is registered under the 1933
Act pursuant to the Registration Statement, and all of the Common Shares and Series B Securities are freely transferable and
freely tradable by the Buyer without restriction. The Registration Statement was declared effective under the 1933 Act by the
SEC on June 21, 2019. The Company has not received from the SEC any notice pursuant to Rule 401(g)(1) under the 1933 Act
objecting to the use of the shelf registration statement form. No stop order suspending the effectiveness of the Registration
Statement or any related registration statement filed by the Company with the SEC under Rule 462(b) under the 1933 Act is in
effect and no proceedings for such purpose have been instituted or are pending or, to the knowledge of the Company, are
contemplated or threatened by the SEC. At the time of (i) the initial filing of the Registration Statement with the SEC and
the most recent amendment thereto for the purposes of complying with Section 10(a)(3) of the 1933 Act (whether such amendment
was by post-effective amendment, incorporated report filed pursuant to Section 13 or 15(d) of the 1934 Act or form of
prospectus), the Company met the then applicable requirements for use of Form S-3 under the 1933 Act. The Company and the
offer, issuance and sale of the Common Shares and Series B Stock to the Buyer hereunder meet the requirements for and comply
with the applicable conditions set forth in Form S-3 under the 1933 Act, including compliance with General Instructions I.A
and I.B.6. of Form S-3. The Registration Statement and the offer, issuance and sale of the Common Shares meet the
requirements of Rule 415(a)(1)(x) under the 1933 Act and comply in all material respects with said Rule. The Registration
Statement is effective and available for the offer, issuance and sale of all of the Common Shares and the Company has not
received any notice that the SEC has issued or intends to issue a stop-order with respect to the Registration Statement or
that the SEC otherwise has suspended or withdrawn the effectiveness of the Registration Statement, either temporarily or
permanently, or intends or has threatened in writing to do so. The “Plan of Distribution” section under the
Registration Statement permits the issuance and sale of the Common Shares and Series B Stock hereunder. At the time the
Registration Statement and any amendment thereto became effective and on the date of this Agreement, the Registration
Statement and any amendment thereto complied and complies in all material respects with the requirements of the 1933 Act and
did not and does not contain any untrue statement of a material fact or omit to state any material fact required to be stated
therein or necessary to make the statements therein not misleading. The Prospectus and any amendment or supplements thereto
(including, without limitation the Prospectus Supplement), at the time the Prospectus or any amendment or supplement thereto
was issued and on the date of this Agreement, complied and complies in all material respects with the requirements of the
1933 Act and did not and does not contain any untrue statement of a material fact or omit to state a material fact necessary
in order to make the statements therein, in light of the circumstances under which they were made, not misleading. At the
earliest time after the filing of the Registration Statement that the Company or another offering participant made a bona
fide offer (within the meaning of Rule 164(h)(2) under the 1933 Act) relating to the Common Shares and the Series B Stock,
the Company was not and is not an “Ineligible Issuer” (as defined in Rule 405 under the 1933 Act). The Company
has not distributed any offering material in connection with the offer or sale of the Common Shares and Series B Stock, other
than the Registration Statement, the Prospectus and the Prospectus Supplement.

 

    -6- 

     

    

 

d.                 
No Conflicts. The execution, delivery and performance of the Transaction Documents by the Company and the consummation
by the Company of the transactions contemplated hereby and thereby (including, without limitation, the offer and sale of the Common
Shares, the offer and sale of the Series B Securities and the Warrant Securities and the reservation for issuance and issuance
of the Series B Preferred Shares and the Warrant Shares issuable upon conversion of the Series B Stock and exercise of the Warrants,
respectively) will not (i) result in a violation of the Certificate of Incorporation (as defined below) (including, without limitation,
any certificate of designation contained therein), Bylaws (as defined below), or the certificate of incorporation, certificate
of formation, memorandum of association, articles of association, bylaws or other organizational documents of any of the Company’s
Subsidiaries, or any capital stock or other securities of the Company or any of its Subsidiaries, (ii) conflict with, or constitute
a default (or an event which with notice or lapse of time or both would become a default) in any respect under, or give to others
any rights of termination, amendment, acceleration or cancellation of, any agreement, indenture or instrument to which the Company
or any of its Subsidiaries is a party, or result in a violation of any law, rule, regulation, order, judgment or decree (including,
without limitation, foreign, federal and state securities laws and regulations and the rules and regulations of the Principal Market
and including all applicable foreign, federal and state laws, rules and regulations) applicable to the Company or any of its Subsidiaries
or by which any property or asset of the Company or any of its Subsidiaries is bound or affected.

 

    -7- 

     

    

 

e.                   Consents.
Neither the Company nor any Subsidiary is required to obtain any consent from, authorization or order of, or make any filing
or registration with (other than (i) the filing with the SEC of the Prospectus Supplement relating to the offer, issuance and
sale of the Common Shares and Series B Stock to the Buyer, (ii) the filing with the SEC of a Form D relating to the offer,
issuance and sale of the Warrant Securities to the Buyer pursuant to Regulation D, (iii) the filing of a Notice of Additional
Listing with the Principal Market and (iv) any other filings as may be required by any state securities authorities), any
Governmental Entity (as defined below) or any regulatory or self-regulatory agency or any other Person in order for it to
execute, deliver or perform any of its respective obligations under or contemplated by the Transaction Documents, in each
case, in accordance with the terms hereof or thereof. All consents, authorizations, orders, filings and registrations which
the Company or any Subsidiary is required to obtain pursuant to the preceding sentence have been or will be obtained or
effected on or prior to the Closing Date, and neither the Company nor any of its Subsidiaries are aware of any facts or
circumstances which might prevent the Company or any of its Subsidiaries from obtaining or effecting any of the registration,
application or filings contemplated by the Transaction Documents. The Company has not been notified of any violation of the
requirements of the Principal Market and has no knowledge of any facts or circumstances which could reasonably lead to
delisting or suspension of the Common Stock in the foreseeable future. “Governmental Entity” means any
nation, state, county, city, town, village, district, or other political jurisdiction of any nature, federal, state, local,
municipal, foreign, or other government, governmental or quasi-governmental authority of any nature (including any
governmental agency, branch, department, official, or entity and any court or other tribunal), multi-national organization or
body; or body exercising, or entitled to exercise, any administrative, executive, judicial, legislative, police, regulatory,
or taxing authority or power of any nature or instrumentality of any of the foregoing, including any entity or enterprise
owned or controlled by a government or a public international organization or any of the foregoing.

 

f.                   
Acknowledgment Regarding Buyer’s Purchase of Securities. The Company acknowledges and agrees that the Buyer
is acting solely in the capacity of an arm’s length purchaser with respect to the Transaction Documents and the transactions
contemplated hereby and thereby and that the Buyer is not (i) an officer or director of the Company or any of its Subsidiaries,
(ii) an “affiliate” (as defined in Rule 144) of the Company or any of its Subsidiaries or (iii) to its knowledge, a
“beneficial owner” of more than 10% of the shares of Common Stock (as defined for purposes of Rule 13d-3 of the 1934
Act). The Company further acknowledges that the Buyer is not acting as a financial advisor or fiduciary of the Company or any of
its Subsidiaries (or in any similar capacity) with respect to the Transaction Documents and the transactions contemplated hereby
and thereby, and any advice given by the Buyer or any of its representatives or agents in connection with the Transaction Documents
and the transactions contemplated hereby and thereby is merely incidental to the Buyer’s purchase of the Securities. The
Company further represents to the Buyer that the Company’s decision to enter into the Transaction Documents has been based
solely on the independent evaluation by the Company and its representatives.

 

g.                 
No General Solicitation; Placement Agent’s Fees. Neither the Company, nor any of its Subsidiaries or affiliates,
nor any Person acting on its or their behalf, has engaged in any form of general solicitation or general advertising (within the
meaning of Regulation D) in connection with the offer, issuance and sale of the Securities. Neither the Company nor any of its
Subsidiaries has engaged any placement agent or other agent in connection with the offer and sale of any of the Securities contemplated
by the Transaction Documents.

 

    -8- 

     

    

 

h.                 
No Integrated Offering. None of the Company, its Subsidiaries or any of their affiliates, nor any Person acting
on their behalf has, directly or indirectly, made any offers or sales of any security or solicited any offers to buy any security,
under circumstances that would cause the issuance of any of the Securities to require approval of stockholders of the Company
under any applicable stockholder approval laws, rules or regulations, including, without limitation, under the rules of any exchange
or automated quotation system on which any securities of the Company are listed or designated for quotation. None of the Company,
its Subsidiaries or any of their affiliates, nor any Person acting on their behalf has, directly or indirectly, made any offers,
issuances or sales of any security (including, without limitation, the offer, issuance and sale of the Common Shares to the Buyer
hereunder) or solicited any offers to buy any security (including, without limitation, any of the Common Shares), under circumstances
that would require registration of the offer, issuance or sale of the Warrant Securities under the 1933 Act, whether through integration
with the offering of the Common Shares to the Buyer hereunder pursuant to the Registration Statement, any prior offering of securities
of the Company or otherwise.

 

i.                   Dilutive Effect. The Company understands and acknowledges that the number of Series B Preferred Shares and the Warrant
Shares will increase in certain circumstances. The Company further acknowledges that its obligation to issue the Series B Preferred
Shares and the Warrant Shares upon conversion of the Series B Stock and exercise of the Warrants, respectively, in accordance with
this Agreement and the Series B Stock and Warrants, in each case, is absolute and unconditional regardless of the dilutive effect
that such issuance may have on the ownership interests of other stockholders of the Company.

 

j.                   Application
of Takeover Protections; Rights Agreement. The Company does not have in effect any control share acquisition, interested stockholder,
business combination, poison pill (including, without limitation, any distribution under a rights agreement), stockholder
rights plan or other similar anti- takeover provision under the Certificate of Incorporation, Bylaws or other organizational documents
or the laws of the jurisdiction of its incorporation or otherwise which is or could become applicable to the Buyer as a result
of the transactions contemplated by this Agreement. The Company does not have in effect any stockholder rights plan or similar
arrangement relating to accumulations of beneficial ownership of shares of Common Stock or a change in control of the Company
or any of its Subsidiaries.

 

    -9- 

     

    

 

k.                  SEC
Documents; Financial Statements. During the two (2) years prior to the date hereof, except as would not reasonably be
expected to have a Material Adverse Effect, the Company has timely filed all reports, schedules, forms, proxy statements,
statements and other documents required to be filed by it with the SEC pursuant to the reporting requirements of the 1934 Act
(all of the foregoing filed prior to the date hereof and all exhibits and appendices included therein and financial
statements, notes and schedules thereto and documents incorporated by reference therein being hereinafter referred to as the
“SEC Documents”). As of their respective dates, the SEC Documents complied in all material respects with
the requirements of the 1934 Act and the rules and regulations of the SEC promulgated thereunder applicable to the SEC
Documents, and none of the SEC Documents, at the time they were filed with the SEC, contained any untrue statement of a
material fact or omitted to state a material fact required to be stated therein or necessary in order to make the statements
therein, in the light of the circumstances under which they were made, not misleading. As of their respective dates, the
financial statements of the Company included in the SEC Documents complied in all material respects with applicable
accounting requirements and the published rules and regulations of the SEC with respect thereto as in effect as of the time
of filing. Such financial statements have been prepared in accordance with generally accepted accounting principles
(“GAAP”), consistently applied, during the periods involved (except (i) as may be otherwise indicated in
such financial statements or the notes thereto, or (ii) in the case of unaudited interim statements, to the extent they may
exclude footnotes or may be condensed or summary statements) and fairly present in all material respects the financial
position of the Company as of the dates thereof and the results of its operations and cash flows for the periods then ended
(subject, in the case of unaudited statements, to normal year-end audit adjustments which will not be material, either
individually or in the aggregate). The reserves, if any, established by the Company or the lack of reserves, if applicable,
are reasonable based upon facts and circumstances known by the Company on the date hereof and there are no loss contingencies
that are required to be accrued by the Statement of Financial Accounting Standard No. 5 of the Financial Accounting Standards
Board which are not provided for by the Company in its financial statements or otherwise. No other information provided by or
on behalf of the Company to the Buyer which is not included in the SEC Documents (including, without limitation, information
in the disclosure schedules to this Agreement) contains any untrue statement of a material fact or omits to state any
material fact necessary in order to make the statements therein not misleading, in the light of
the circumstance under which they are or were made. The Company is not currently contemplating to amend or restate any of the
financial statements (including, without limitation, any notes or any letter of the independent accountants of the Company
with respect thereto) included in the SEC Documents (the “Financial Statements”), nor is the Company
currently aware of facts or circumstances which would require the Company to amend or restate any of the Financial
Statements, in each case, in order for any of the Financials Statements to be in compliance with GAAP and the rules and
regulations of the SEC. The Company has not been informed by its independent accountants that they recommend that the Company
amend or restate any of the Financial Statements or that there is any need for the Company to amend or restate any of the
Financial Statements.

 

l.                    Absence
of Certain Changes. Since the date of the Company’s most recent audited financial statements contained in a Form
10-K, except as disclosed in the SEC Documents, there has been no material adverse change and no material adverse development
in the business, assets, liabilities, properties, operations (including results thereof), condition (financial or otherwise)
or prospects of the Company or any of its Subsidiaries. Since the date of the Company’s most recent audited financial
statements contained in a Form 10-K, neither the Company nor any of its Subsidiaries has (i) sold any assets, individually or
in the aggregate, outside of the ordinary course of business or (ii) made any capital expenditures, individually or in the
aggregate, outside of the ordinary course of business. Neither the Company nor any of its Subsidiaries has taken any steps to
seek protection pursuant to any law or statute relating to bankruptcy, insolvency, reorganization, receivership, liquidation
or winding up, nor does the Company or any Subsidiary have any knowledge or reason to believe that any of their respective
creditors intend to initiate involuntary bankruptcy proceedings or any actual knowledge of any fact which would reasonably
lead a creditor to do so. The Company and its Subsidiaries, individually and on a consolidated basis, are not as of the date
hereof, and after giving effect to the transactions contemplated hereby to occur at the Closing, will not be Insolvent (as
defined below). For purposes of this Section 3(l), “Insolvent” means, (i) with respect to the Company and
its Subsidiaries, on a consolidated basis, the present fair saleable value of the Company’s and its Subsidiaries’
assets is less than the amount required to pay the Company’s and its Subsidiaries’ total Indebtedness (as defined
below), the Company and its Subsidiaries are unable to pay their debts and liabilities, subordinated, contingent or
otherwise, as such debts and liabilities become absolute and matured or (C) the Company and its Subsidiaries intend to incur
or believe that they will incur debts that would be beyond their ability to pay as such debts mature; and (ii) with respect
to the Company and each Subsidiary, individually, (A) the present fair saleable value of the Company’s or such
Subsidiary’s (as the case may be) assets is less than the amount required to pay its respective total Indebtedness, (B)
the Company or such Subsidiary (as the case may be) is unable to pay its respective debts and liabilities, subordinated,
contingent or otherwise, as such debts and liabilities become absolute and matured or (C) the Company or such Subsidiary (as
the case may be) intends to incur or believes that it will incur debts that would be beyond its respective ability to pay as
such debts mature. Neither the Company nor any of its Subsidiaries has engaged in any business or
in any transaction, and is not about to engage in any business or in any transaction, for which the Company’s or such
Subsidiary’s remaining assets constitute unreasonably small capital with which to conduct the business in which it is
engaged as such business is now conducted and is proposed to be conducted.

 

    -10- 

     

    

 

m.               
No Undisclosed Events, Liabilities, Developments or Circumstances. No event, liability, development or circumstance
has occurred or exists, with respect to the Company, any of its Subsidiaries or any of their respective businesses, properties,
liabilities, prospects, operations (including results thereof) or condition (financial or otherwise), that (i) would be required
to be disclosed by the Company under applicable securities laws on a registration statement on Form S-1 filed with the SEC relating
to an issuance and sale by the Company of its Common Stock and which has not been publicly announced, (ii) could have a material
adverse effect on the Buyer’s investment hereunder or (iii) could have a Material Adverse Effect.

 

n.                 
Conduct of Business; Regulatory Permits. Neither the Company nor any of its Subsidiaries is in violation of any term
of or in default under its Certificate of Incorporation, any certificate of designation, preferences or rights of any other outstanding
series of preferred stock of the Company, or any organizational charter, certificate of formation, memorandum of association, articles
of association, certificate of incorporation or bylaws of any of the Subsidiaries. Neither the Company nor any of its Subsidiaries
is in violation of any judgment, decree or order or any statute, ordinance, rule or regulation applicable to the Company or any
of its Subsidiaries, and neither the Company nor any of its Subsidiaries will conduct its business in violation of any of the foregoing,
except in all cases for possible violations which could not, individually or in the aggregate, have a Material Adverse Effect.
The Company and each of its Subsidiaries possess all certificates, authorizations and permits issued by the appropriate regulatory
authorities necessary to conduct their respective businesses, except where the failure to possess such certificates, authorizations
or permits would not have, individually or in the aggregate, a Material Adverse Effect, and neither the Company nor any such Subsidiary
has received any notice of proceedings relating to the revocation or modification of any such certificate, authorization or permit.
There is no agreement, commitment, judgment, injunction, order or decree binding upon the Company or any of its Subsidiaries or
to which the Company or any of its Subsidiaries is a party which has or would reasonably be expected to have the effect of prohibiting
or materially impairing any business practice of the Company or any of its Subsidiaries, any acquisition of property by the Company
or any of its Subsidiaries or the conduct of business by the Company or any of its Subsidiaries as currently conducted other than
such effects, individually or in the aggregate, which have not had and would not reasonably be expected to have a Material Adverse
Effect on the Company or any of its Subsidiaries.

 

    -11- 

     

    

 

o.                 
 Foreign Corrupt Practices. Neither the Company, any of its Subsidiaries or to the knowledge of the Company, any
director, officer, agent, employee, nor any other person acting for or on behalf of the foregoing (individually and collectively,
a “Company Affiliate”) have violated the U.S. Foreign Corrupt Practices Act or any other applicable anti-bribery
or anti- corruption laws, nor has any Company Affiliate offered, paid, promised to pay, or authorized the payment of any money,
or offered, given, promised to give, or authorized the giving of anything of value, to any officer, employee or any other person
acting in an official capacity for any Governmental Entity to any political party or official thereof or to any candidate for political
office (individually and collectively, a “Government Official”) or to any person under circumstances where such
Company Affiliate knew or was aware of a high probability that all or a portion of such money or thing of value would be offered,
given or promised, directly or indirectly, to any Government Official, for the purpose of:

 

i.                  
(A) influencing any act or decision of such Government Official in his/her official capacity, (B) inducing such Government
Official to do or omit to do any act in violation of his/her lawful duty, (C) securing any improper advantage, or (D) inducing
such Government Official to influence or affect any act or decision of any Governmental Entity, or

 

ii.                 
assisting the Company or its Subsidiaries in obtaining or retaining business for or with, or directing business to, the
Company or its Subsidiaries.

 

p.                 
Sarbanes-Oxley Act. The Company and each Subsidiary is in compliance in all material respects with any and all applicable
requirements of the Sarbanes-Oxley Act of 2002, as amended, and any and all applicable rules and regulations promulgated by the
SEC thereunder.

 

q.                  Transactions
With Affiliates. Except as disclosed in the SEC Documents, no current or former employee, partner, director, officer or
stockholder (direct or indirect) of the Company or its Subsidiaries, or any associate, or, to the knowledge of the Company,
any affiliate of any thereof, or any relative with a relationship no more remote than first cousin of any of the foregoing,
is presently, or has ever been, (i) a party to any transaction with the Company or its Subsidiaries (including any contract,
agreement or other arrangement providing for the furnishing of services by, or rental of real or personal property from, or
otherwise requiring payments to, any such director, officer or stockholder or such associate or affiliate or relative
Subsidiaries (other than for ordinary course services as employees, officers or directors of the Company or any of its
Subsidiaries, including equity compensation and the like)) or (ii) the direct or indirect owner of an interest in any
corporation, firm, association or business organization which is a competitor, supplier or customer of the Company or its
Subsidiaries (except for a passive investment (direct or indirect) in less than 5% of the common stock of a company whose
securities are traded on or quoted through an Eligible Market (as defined below)), nor does any such Person receive income
from any source other than the Company or its Subsidiaries which relates to the business of the Company or its Subsidiaries
or should properly accrue to the Company or its Subsidiaries. No employee, officer, stockholder or director of the Company or
any of its Subsidiaries or member of his or her immediate family is indebted to the Company or its Subsidiaries, as the case
may be, nor is the Company or any of its Subsidiaries indebted (or committed to make loans or extend or guarantee credit) to
any of them, other than (i) for payment of salary for services rendered, (ii) reimbursement for
reasonable expenses incurred on behalf of the Company, and (iii) for other standard employee benefits made generally
available to all employees or executives (including stock option agreements outstanding under any stock option plan approved
by the Board of Directors of the Company).

 

    -12- 

     

    

 

r.                   
Equity Capitalization.

 

i.                   
Definitions:

 

1.                 
“Common Stock” means (x) the Company’s shares of common stock, $0.0001 par value per share, and
(y) any capital stock into which such common stock shall have been changed or any share capital resulting from a reclassification
of such common stock.

 

2.                 
“Preferred Stock” means (x) the Company’s blank check preferred stock, $0.001 par value per share,
the terms of which may be designated by the board of directors of the Company in a certificate of designations and (y) any capital
stock into which such preferred stock shall have been changed or any share capital resulting from a reclassification of such preferred
stock (other than a conversion of such preferred stock into Common Stock in accordance with the terms of such certificate of designations).

 

ii.                 
Authorized and Outstanding Capital Stock. As of the date hereof, the authorized capital stock of the Company consists
of (A) 100,000,000 shares of Common Stock, of which 4,863,984 are issued and outstanding (excluding the Common Shares) and 4,948,525
shares are reserved for issuance pursuant to Convertible Securities (as defined below) (excluding the Warrant Shares) exercisable
or exchangeable for, or convertible into, shares of Common Stock, and (B) 5,000,000 shares of Preferred Stock, 2,990,000 of which
are designated as 6% Convertible Exchangeable Preferred Stock, 335,273 of which are issued and outstanding, and 8,872 are designated
as Series A Convertible Preferred Stock, 264 of which are issued and outstanding (excluding the Series B Stock to be issued hereunder).
0 shares of Common Stock are held in the treasury of the Company. Convertible Securities means the Company’s (i) 6% Convertible
Exchangeable Preferred Stock, (ii) Series A Convertible Preferred Stock, (iii) restricted stock units, (iv) warrants to purchase
shares of Common Stock (other than the Warrants), and (v) options to purchase shares of Common Stock.

 

iii.                Valid
Issuance; Available Shares; Affiliates. All of such outstanding shares are duly authorized and have been, or upon
issuance will be, validly issued and are fully paid and nonassessable. The SEC Documents set forth, as of the date(s)
described therein, sets forth the number of shares of Common Stock that are (A) reserved for issuance pursuant to
Convertible Securities and (B) that are, as of the date hereof, owned by Persons who are
“affiliates” (as defined in Rule 405 of the 1933 Act and calculated based on the assumption that only officers,
directors and holders of at least 10% of the Company’s issued and outstanding Common Stock are “affiliates”
without conceding that any such Persons are “affiliates” for purposes of federal securities laws) of the Company
or any of its Subsidiaries. To the Company’s knowledge, no Person owns 10% or more of the Company’s issued and
outstanding shares of Common Stock (calculated based on the assumption that all Convertible Securities, whether or not
presently exercisable or convertible, have been fully exercised or converted (as the case may be) taking account of any
limitations on exercise or conversion (including “blockers”) contained therein without conceding that such
identified Person is a 10% stockholder for purposes of federal securities laws).

 

    -13- 

     

    

 

iv.               
Existing Securities; Obligations. Except as disclosed in the SEC Documents: (A) none of the Company’s or any
Subsidiary’s shares, interests or capital stock is subject to preemptive rights or any other similar rights or Liens suffered
or permitted by the Company or any Subsidiary; (B) there are no outstanding options, warrants, scrip, rights to subscribe to, calls
or commitments of any character whatsoever relating to, or securities or rights convertible into, or exercisable or exchangeable
for, any shares, interests or capital stock of the Company or any of its Subsidiaries, or contracts, commitments, understandings
or arrangements by which the Company or any of its Subsidiaries is or may become bound to issue additional shares, interests or
capital stock of the Company or any of its Subsidiaries or options, warrants, scrip, rights to subscribe to, calls or commitments
of any character whatsoever relating to, or securities or rights convertible into, or exercisable or exchangeable for, any shares,
interests or capital stock of the Company or any of its Subsidiaries; (C) there are no agreements or arrangements under which the
Company or any of its Subsidiaries is obligated to register the sale of any of their securities under the 1933 Act (except pursuant
to this Agreement); (D) there are no outstanding securities or instruments of the Company or any of its Subsidiaries which contain
any redemption or similar provisions, and there are no contracts, commitments, understandings or arrangements by which the Company
or any of its Subsidiaries is or may become bound to redeem a security of the Company or any of its Subsidiaries; (E) there are
no securities or instruments containing anti-dilution or similar provisions that will be triggered by the issuance of any or all
of the Securities; and (F) neither the Company nor any Subsidiary has any stock appreciation rights or “phantom stock”
plans or agreements or any similar plan or agreement.

 

v.                 
Organizational Documents. The Company has furnished to the Buyer, if so requested, true, correct and complete copies
of the Company’s Certificate of Incorporation, as amended and as in effect on the date hereof (the “Certificate
of Incorporation”), and the Company’s bylaws, as amended and as in effect on the date hereof (the “Bylaws”),
and the terms of all Convertible Securities and the material rights of the holders thereof in respect thereto.

 

    -14- 

     

    

 

 

vi.                Indebtedness
and Other Contracts. Neither the Company nor any of its Subsidiaries, except as set forth in the SEC Documents, has any
outstanding debt securities, notes, credit agreements, credit facilities or other agreements, documents or instruments evidencing
Indebtedness of the Company or any of its Subsidiaries or by which the Company or any of its Subsidiaries is or may become
bound, (ii) is a party to any contract, agreement or instrument, the violation of which, or default under which, by the other
party(ies) to such contract, agreement or instrument could reasonably be expected to result in a Material Adverse Effect,
(iii) has any financing statements securing obligations in any amounts filed in connection with the Company or any of its
Subsidiaries; (iv) is in violation of any term of, or in default under, any contract, agreement or instrument relating to any
Indebtedness, except where such violations and defaults would not result, individually or in the aggregate, in a Material
Adverse Effect, or (v) is a party to any contract, agreement or instrument relating to any Indebtedness, the performance of
which, in the judgment of the Company’s officers, has or is expected to have a Material Adverse Effect. Neither the
Company nor any of its Subsidiaries have any liabilities or obligations required to be disclosed in the SEC Documents which
are not so disclosed in the SEC Documents, other than those incurred in the ordinary course of the Company’s or its
Subsidiaries’ respective businesses and which, individually or in the aggregate, do not or could not have a Material
Adverse Effect. For purposes of this Agreement: (x) “Indebtedness” of any Person means, without
duplication (A) all indebtedness for borrowed money, (B) all obligations issued, undertaken or assumed as the deferred
purchase price of property or services (including, without limitation, “capital leases” in accordance with GAAP)
(other than trade payables entered into in the ordinary course of business consistent with past practice), (C) all
reimbursement or payment obligations with respect to letters of credit, surety bonds and other similar instruments, (D) all
obligations evidenced by notes, bonds, debentures or similar instruments, including obligations so evidenced incurred in
connection with the acquisition of property, assets or businesses, (E) all indebtedness created or arising under any
conditional sale or other title retention agreement, or incurred as financing, in either case with respect to any property or
assets acquired with the proceeds of such indebtedness (even though the rights and remedies of the seller or bank under such
agreement in the event of default are limited to repossession or sale of such property), (F) all monetary obligations under
any leasing or similar arrangement which, in connection with GAAP, consistently applied for the periods covered thereby, is
classified as a capital lease, (G) all indebtedness referred to in clauses (A) through (F) above secured by (or for which the
holder of such Indebtedness has an existing right, contingent or otherwise, to be secured by) any Lien upon or in any
property or assets (including accounts and contract rights) owned by any Person, even though the Person which owns such
assets or property has not assumed or become liable for the payment of such indebtedness, and (H) all Contingent Obligations
in respect of indebtedness or obligations of others of the kinds referred to in clauses (A) through (G) above; (y)
“Contingent Obligation” means, as to any Person, any direct or indirect liability, contingent or
otherwise, of that Person with respect to any Indebtedness, lease, dividend or other obligation of another Person if the
primary purpose or intent of the Person incurring such liability, or the primary effect thereof, is to provide assurance to
the obligee of such liability that such liability will be paid or discharged, or that any agreements relating thereto will be
complied with, or that the holders of such liability will be protected (in whole or in part) against loss with respect
thereto; and (z) “Person” means an individual, a limited liability company, a partnership, a joint
venture, a corporation, a trust, an unincorporated organization, any other entity and any Governmental Entity or any
department or agency thereof.

 

vii.              Litigation.
There is no action, suit, arbitration, proceeding, inquiry or investigation before or by the Principal Market, any court,
public board, other Governmental Entity, self- regulatory organization or body pending or, to the knowledge of the Company,
threatened against or affecting the Company or any of its Subsidiaries, the Common Stock or any of the Company’s or its
Subsidiaries’ officers or directors, whether of a civil or criminal nature or otherwise, in their capacities as such,
which is outside of the ordinary course of business or individually or in the aggregate material to the Company or any of its
Subsidiaries. To the Company’s knowledge, no director, officer or employee of the Company or any of its Subsidiaries
has willfully violated 18 U.S.C. §1519 or engaged in spoliation in reasonable anticipation of litigation. Without
limitation of the foregoing, there has not been, and to the knowledge of the Company, there is not pending or contemplated,
any investigation by the SEC involving the Company, any of its Subsidiaries or any current or former director or officer of
the Company or any of its Subsidiaries. The SEC has not issued any stop order or other order suspending the effectiveness of
any registration statement filed by the Company under the 1933 Act or the 1934 Act, including, without limitation, the
Registration Statement. After reasonable inquiry of its employees, the Company is not aware of any fact which might result in
or form the basis for any such action, suit, arbitration, investigation, inquiry or other proceeding. Neither the Company nor
any of its Subsidiaries is subject to any order, writ, judgment, injunction, decree, determination or award of any
Governmental Entity.

 

    -15-

     

    

 

viii.           
Insurance. The Company and each of its Subsidiaries are insured by insurers of recognized financial responsibility
against such losses and risks and in such amounts as management of the Company believes to be prudent and customary in the businesses
in which the Company and its Subsidiaries are engaged. Neither the Company nor any such Subsidiary has been refused any insurance
coverage sought or applied for, and neither the Company nor any such Subsidiary has any reason to believe that it will be unable
to renew its existing insurance coverage as and when such coverage expires or to obtain similar coverage from similar insurers
as may be necessary to continue its business at a cost that would not have a Material Adverse Effect.

 

ix.               
Employee Relations. Neither the Company nor any of its Subsidiaries is a party to any collective bargaining agreement
or employs any member of a union. The Company and its Subsidiaries believe that their relations with their employees are good.
No executive officer (as defined in Rule 501(f) promulgated under the 1933 Act) or other key employee of the Company or any of
its Subsidiaries has notified the Company or any such Subsidiary that such officer intends to leave the Company or any such Subsidiary
or otherwise terminate such officer’s employment with the Company or any such Subsidiary. No executive officer or other key
employee of the Company or any of its Subsidiaries is, or is now expected to be, in violation of any material term of any employment
contract, confidentiality, disclosure or proprietary information agreement, non-competition agreement, or any other contract or
agreement or any restrictive covenant, and the continued employment of each such executive officer or other key employee (as the
case may be) does not subject the Company or any of its Subsidiaries to any liability with respect to any of the foregoing matters.
The Company and its Subsidiaries are in compliance with all federal, state, local and foreign laws and regulations respecting labor,
employment and employment practices and benefits, terms and conditions of employment and wages and hours, except where failure
to be in compliance would not, either individually or in the aggregate, reasonably be expected to result in a Material Adverse
Effect.

 

x.                 
[Intentionally Omitted.]

 

xi.                Real
Property. Each of the Company and its Subsidiaries holds good title to all real property, leases in real property,
facilities or other interests in real property owned or held by the Company or any of its Subsidiaries (the “Real
Property”) owned by the Company or any of its Subsidiaries (as applicable). The Real Property is free and clear of
all Liens and is not subject to any rights of way, building use restrictions, exceptions, variances, reservations, or
limitations of any nature except for (a) Liens for current taxes not yet due and (b) zoning laws and other land use
restrictions that do not impair the present or anticipated use of the property subject thereto. Any Real Property held under
lease by the Company or any of its Subsidiaries are held by them under valid, subsisting and enforceable leases with such
exceptions as are not material and do not interfere with the use made and proposed to be made of such property and buildings
by the Company or any of its Subsidiaries.

 

    -16-

     

    

 

xii.             
Fixtures and Equipment. Each of the Company and its Subsidiaries (as applicable) has good title to, or a valid leasehold
interest in, the tangible personal property, equipment, improvements, fixtures, and other personal property and appurtenances that
are used by the Company or its Subsidiary in connection with the conduct of its business (the “Fixtures and Equipment”).
The Fixtures and Equipment are structurally sound, are in good operating condition and repair, are adequate for the uses to which
they are being put, are not in need of maintenance or repairs except for ordinary, routine maintenance and repairs and are sufficient
for the conduct of the Company’s and/or its Subsidiaries’ businesses (as applicable) in the manner as conducted prior
to the Closing. Each of the Company and its Subsidiaries owns all of its Fixtures and Equipment free and clear of all Liens except
for (a) Liens for current taxes not yet due and (b) zoning laws and other land use restrictions that do not impair the present
or anticipated use of the property subject thereto.

 

xiii.            FDA.
As to each product subject to the jurisdiction of the U.S. Food and Drug Administration (“FDA”) under the
Federal Food, Drug and Cosmetic Act, as amended, and the regulations thereunder (“FDCA”) that is
manufactured, packaged, labeled, tested, distributed, sold, and/or marketed by the Company or any of its Subsidiaries (each
such product, a “Pharmaceutical Product”), such Pharmaceutical Product is being manufactured, packaged,
labeled, tested, distributed, sold and/or marketed by the Company in compliance with all applicable requirements under FDCA
and similar laws, rules and regulations relating to registration, investigational use, premarket clearance, licensure, or
application approval, good manufacturing practices, good laboratory practices, good clinical practices, product listing,
quotas, labeling, advertising, record keeping and filing of reports, except where the failure to be in compliance would not
have a Material Adverse Effect. There is no pending, completed or, to the Company’s knowledge, threatened, action
(including any lawsuit, arbitration, or legal or administrative or regulatory proceeding, charge, complaint, or
investigation) against the Company or any of its Subsidiaries, and none of the Company or any of its Subsidiaries has
received any notice, warning letter or other communication from the FDA or any other governmental entity, which (i) contests
the premarket clearance, licensure, registration, or approval of, the uses of, the distribution of, the manufacturing or
packaging of, the testing of, the sale of, or the labeling and promotion of any Pharmaceutical Product, (ii) withdraws its
approval of, requests the recall, suspension, or seizure of, or withdraws or orders the withdrawal of advertising or sales
promotional materials relating to, any Pharmaceutical Product, (iii) imposes a clinical hold on any clinical investigation by
the Company or any of its Subsidiaries, (iv) enjoins production at any facility of the Company or any of its Subsidiaries,
(v) enters or proposes to enter into a consent decree of permanent injunction with the Company or any of its Subsidiaries, or
(vi) otherwise alleges any violation of any laws, rules or regulations by the Company or any of its Subsidiaries, and which,
either individually or in the aggregate, would have a Material Adverse Effect. The properties, business and operations of the
Company have been and are being conducted in all material respects in accordance with all applicable laws, rules and
regulations of the FDA. The Company has not been informed by the FDA that the FDA will prohibit the marketing, sale, license
or use in the United States of any product proposed to be developed, produced or marketed by the Company nor has the FDA
expressed any concern as to approving or clearing for marketing any product being developed or proposed to be developed by
the Company.

 

    -17-

     

    

 

(a)              
Clinical Data and Regulatory Compliance. The preclinical tests
and clinical trials, and other studies (collectively, “studies”) that are described in, or the results of which are
referred to in, the SEC Reports were and, if still pending, are being conducted in all material respects in accordance with the
protocols, procedures and controls designed and approved for such studies and with standard medical and scientific research procedures;
each description of the results of such studies is accurate and complete in all material respects and fairly presents the data
derived from such studies, and the Company and its Subsidiaries have no knowledge of any other studies the results of which are
inconsistent with, or otherwise call into question, the results described or referred to in the SEC Reports; the Company and its
Subsidiaries have made all such filings and obtained all such approvals as may be required by the FDA or any committee thereof
or from any other U.S. or non-U.S. government or drug or medical device regulatory agency, or health care facility Institutional
Review Board (collectively, the “Regulatory Agencies”); neither the Company nor any of its Subsidiaries has
received any notice of, or correspondence from, any Regulatory Agency requiring the termination, suspension or modification of
any clinical trials that are described or referred to in the SEC Reports; and the Company and its Subsidiaries have each operated
and currently are in compliance in all material respects with all applicable rules, regulations and policies of the Regulatory
Agencies.

 

xiv.           
Intellectual Property Rights. The Company and its Subsidiaries own or possess adequate rights or licenses to use
all trademarks, trade names, service marks, service mark registrations, service names, original works of authorship, patents, patent
rights, copyrights, inventions, licenses, approvals, governmental authorizations, trade secrets and other intellectual property
rights and all applications and registrations therefor (“Intellectual Property Rights”) necessary to conduct
their respective businesses as now conducted. None of the Company’s Intellectual Property Rights have expired or terminated
or have been abandoned or are expected to expire or terminate or are expected to be abandoned, within three years from the date
of this Agreement. The Company does not have any knowledge of any infringement by the Company or its Subsidiaries of Intellectual
Property Rights of others. There is no claim, action or proceeding being made or brought, or to the knowledge of the Company or
any of its Subsidiaries, being threatened, against the Company or any of its Subsidiaries regarding
its Intellectual Property Rights. Neither the Company nor any of its Subsidiaries is aware of any facts or circumstances which
might give rise to any of the foregoing infringements or claims, actions or proceedings. The Company and its Subsidiaries have
taken reasonable security measures to protect the secrecy, confidentiality and value of all of their Intellectual Property Rights.

 

    -18-

     

    

 

xv.             
 Environmental Laws. The Company and its Subsidiaries (i) are in compliance with all federal, state, local and foreign
laws relating to pollution or protection of human health or the environment (including ambient air, surface water, groundwater,
land surface or subsurface strata), including laws relating to emissions, discharges, releases or threatened releases of chemicals,
pollutants, contaminants, or toxic or hazardous substances or wastes (collectively, “Hazardous Materials”) into
the environment, or otherwise relating to the manufacture, processing, distribution, use, treatment, storage, disposal, transport
or handling of Hazardous Materials, as well as all authorizations, codes, decrees, demands, or demand letters, injunctions, judgments,
licenses, notices or notice letters, orders, permits, plans or regulations, issued, entered, promulgated or approved thereunder
(“Environmental Laws”); (ii) have received all permits licenses or other approvals required of them under applicable
Environmental Laws to conduct their respective businesses; and (iii) are in compliance with all terms and conditions of any such
permit, license or approval where in each clause (i), (ii) and (iii), the failure to so comply could be reasonably expected to
have, individually or in the aggregate, a Material Adverse Effect.

 

s.                  
[Intentionally Omitted.]

 

t.                   
Tax Status. The Company and each of its Subsidiaries (i) has timely made or filed all foreign, federal and state
income and all other tax returns, reports and declarations required by any jurisdiction to which it is subject, (ii) has timely
paid all taxes and other governmental assessments and charges that are material in amount, shown or determined to be due on such
returns, reports and declarations, except those being contested in good faith and (iii) has set aside on its books provision reasonably
adequate for the payment of all taxes for periods subsequent to the periods to which such returns, reports or declarations apply.
There are no unpaid taxes in any material amount claimed to be due by the taxing authority of any jurisdiction, and the officers
of the Company and its Subsidiaries know of no basis for any such claim. The Company is not operated in such a manner as to qualify
as a passive foreign investment company, as defined in Section 1297 of the U.S. Internal Revenue Code of 1986, as amended (the
“Code”).

 

u.                  Internal
Accounting and Disclosure Controls. The Company and each of its Subsidiaries maintains internal control over financial
reporting (as such term is defined in Rule 13a-15(f) under the 1934 Act) that is effective to provide reasonable assurance
regarding the reliability of financial reporting and the preparation of financial statements for external purposes in
accordance with generally accepted accounting principles, including that (i) transactions are executed in accordance with
management’s general or specific authorizations, (ii) transactions are recorded as necessary
to permit preparation of financial statements in conformity with GAAP and to maintain asset and liability accountability,
(iii) access to assets or incurrence of liabilities is permitted only in accordance with management’s general or
specific authorization, (iv) the recorded accountability for assets and liabilities is compared with the existing assets and
liabilities at reasonable intervals and appropriate action is taken with respect to any difference and (v) the interactive
data in XBRL included or incorporated by reference in the Registration Statement, the Prospectus and the Prospectus
Supplement fairly present the information called for in all material respects and are prepared in accordance with the
SEC’s rules and guidelines applicable thereto. The Company maintains disclosure controls and procedures (as such term
is defined in Rule 13a- 15(e) under the 1934 Act) that are effective in ensuring that information required to be disclosed by
the Company in the reports that it files or submits under the 1934 Act is recorded, processed, summarized and reported,
within the time periods specified in the rules and forms of the SEC, including, without limitation, controls and procedures
designed to ensure that information required to be disclosed by the Company in the reports that it files or submits under the
1934 Act is accumulated and communicated to the Company’s management, including its principal executive officer or
officers and its principal financial officer or officers, as appropriate, to allow timely decisions regarding required
disclosure. Neither the Company nor any of its Subsidiaries has received any notice or correspondence from any accountant,
Governmental Entity or other Person relating to any potential material weakness or significant deficiency in any part of the
internal controls over financial reporting of the Company or any of its Subsidiaries.

 

    -19-

     

    

 

v.                 
Off Balance Sheet Arrangements. There is no transaction, arrangement, or other relationship between the Company or
any of its Subsidiaries and an unconsolidated or other off balance sheet entity that is required to be disclosed by the Company
in its 1934 Act filings and is not so disclosed or that otherwise could be reasonably likely to have a Material Adverse Effect.

 

w.               
Investment Company Status. The Company is not, and upon consummation of the sale of the Securities will not be, an
“investment company,” an affiliate of an “investment company,” a company controlled by an “investment
company” or an “affiliated person” of, or “promoter” or “principal underwriter” for,
an “investment company” as such terms are defined in the Investment Company Act of 1940, as amended.

 

x.                 
Manipulation of Price. Neither the Company nor any of its Subsidiaries has, and, to the knowledge of the Company,
no Person acting on their behalf has, directly or indirectly, (i) taken any action designed to cause or to result in the stabilization
or manipulation of the price of any security of the Company or any of its Subsidiaries to facilitate the sale or resale of any
of the Securities, (ii) sold, bid for, purchased, or paid any compensation for soliciting purchases of, any of the Securities,
(iii) paid or agreed to pay to any Person any compensation for soliciting another to purchase any other securities
of the Company or any of its Subsidiaries or (iv) paid or agreed to pay any Person for research services with respect to any securities
of the Company or any of its Subsidiaries.

 

y.                 
 U.S. Real Property Holding Corporation. Neither the Company nor any of its Subsidiaries is, or has ever been, and
so long as any of the Securities are held by the Buyer, shall become, a U.S. real property holding corporation within the meaning
of Section 897 of the Code, and the Company and each Subsidiary shall so certify upon the Buyer’s request.

 

z.                  
Transfer Taxes. On the Closing Date, all stock transfer or other taxes (other than income or similar taxes) which
are required to be paid in connection with the issuance, sale and transfer of the Securities to be sold to the Buyer hereunder
will be, or will have been, fully paid or provided for by the Company, and all laws imposing such taxes will be or will have been
complied with.

 

aa.               Bank
Holding Company Act. Neither the Company nor any of its Subsidiaries is subject to the Bank Holding Company Act of 1956,
as amended (the “BHCA”) and to regulation by the Board of Governors of the Federal Reserve System (the
“Federal Reserve”). Neither the Company nor any of its Subsidiaries or affiliates owns or controls,
directly or indirectly, five percent (5%) or more of the outstanding shares of any class of voting securities or twenty-five
percent (25%) or more of the total equity of a bank or any entity that is subject to the BHCA and to regulation by the
Federal Reserve. Neither the Company nor any of its Subsidiaries or affiliates exercises a controlling influence over the
management or policies of a bank or any entity that is subject to the BHCA and to regulation by the Federal Reserve.

 

    -20-

     

    

 

bb.             
Shell Company Status. The Company is not, and has never been, an issuer identified in, or subject to, Rule 144(i).

 

cc.              
Illegal or Unauthorized Payments; Political Contributions. Neither the Company nor any of its Subsidiaries nor, to
the Company’s knowledge, any of the officers, directors, employees, agents or other representatives of the Company or any
of its Subsidiaries or any other business entity or enterprise with which the Company or any Subsidiary is or has been affiliated
or associated, has, directly or indirectly, made or authorized any payment, contribution or gift of money, property, or services,
whether or not in contravention of applicable law, (i) as a kickback or bribe to any Person or (ii) to any political organization,
or the holder of or any aspirant to any elective or appointive public office except for personal political contributions not involving
the direct or indirect use of funds of the Company or any of its Subsidiaries.

 

dd.             
Money Laundering. The Company and its Subsidiaries are in compliance with, and have not previously violated, the
USA Patriot Act of 2001 and all other applicable U.S. and non-U.S. anti-money laundering laws and regulations, including, but not
limited to, the laws, regulations and Executive Orders and sanctions programs administered by the U.S. Office of Foreign Assets
Control, including, without limitation, (i) Executive Order 13224 of September 23, 2001 entitled, “Blocking Property and
Prohibiting Transactions With Persons Who Commit, Threaten to Commit, or Support Terrorism” (66 Fed. Reg. 49079 (2001));
and (ii) any regulations contained in 31 CFR, Subtitle B, Chapter V.

 

ee.              
Management. During the past five year period, to the knowledge of the Company, no current officer or director and
no current ten percent (10%) or greater stockholder of the Company or any of its Subsidiaries has been the subject of:

 

i.                   
a petition under bankruptcy laws or any other insolvency or moratorium law or the appointment by a court of a receiver,
fiscal agent or similar officer for such Person, or any partnership in which such person was a general partner at or within two
years before the filing of such petition or such appointment, or any corporation or business association of which such person was
an executive officer at or within two years before the time of the filing of such petition or such appointment;

 

ii.                 
a conviction in a criminal proceeding or a named subject of a pending criminal proceeding (excluding traffic violations
that do not relate to driving while intoxicated or driving under the influence);

 

iii.               
any order, judgment or decree, not subsequently reversed, suspended or vacated, of any court of competent jurisdiction,
permanently or temporarily enjoining any such person from, or otherwise limiting, the following activities:

 

    -21-

     

    

 

1.                 
 Acting as a futures commission merchant, introducing broker, commodity trading advisor, commodity pool operator, floor
broker, leverage transaction merchant, any other person regulated by the United States Commodity Futures Trading Commission or
an associated person of any of the foregoing, or as an investment adviser, underwriter, broker or dealer in securities, or as an
affiliated person, director or employee of any investment company, bank, savings and loan association or insurance company, or
engaging in or continuing any conduct or practice in connection with such activity;

 

iv.               
Engaging in any particular type of business practice; or

 

v.                 
Engaging in any activity in connection with the purchase or sale of any security or commodity or in connection with any
violation of securities laws or commodities laws;

 

vi.               
any order, judgment or decree, not subsequently reversed, suspended or vacated, of any authority barring, suspending or
otherwise limiting for more than sixty (60) days the right of any such person to engage in any activity described in the preceding
sub paragraph, or to be associated with persons engaged in any such activity;

 

vii.             
a finding by a court of competent jurisdiction in a civil action or by the SEC or other authority to have violated any securities
law, regulation or decree and the judgment in such civil action or finding by the SEC or any other authority has not been subsequently
reversed, suspended or vacated; or

 

viii.           
a finding by a court of competent jurisdiction in a civil action or by the Commodity Futures Trading Commission to have
violated any federal commodities law, and the judgment in such civil action or finding has not been subsequently reversed, suspended
or vacated.

 

ff.                
Stock Option Plans. Each stock option granted by the Company was granted (i) in accordance with the terms of the
applicable stock option plan of the Company and (ii) with an exercise price at least equal to the fair market value of the Common
Stock on the date such stock option would be considered granted under GAAP and applicable law. No stock option granted under the
Company’s stock option plan has been backdated. The Company has not knowingly granted, and there is no and has been no policy
or practice of the Company to knowingly grant, stock options prior to, or otherwise knowingly coordinate the grant of stock options
with, the release or other public announcement of material information regarding the Company or its Subsidiaries or their financial
results or prospects.

 

gg.             
No Disagreements with Accountants and Lawyers. There are no material disagreements of any kind presently existing,
or reasonably anticipated by the Company to arise, between the Company and the accountants and lawyers formerly or presently employed
by the Company and the Company is current in all material respects with respect to any fees owed to its accountants and lawyers
which could affect the Company’s ability to perform any of its obligations under any of the Transaction Documents. In addition,
the Company has no reason to believe that it will need to restate any such financial statements or any part thereof.

 

    -22-

     

    

 

hh.             
 No Additional Agreements. The Company does not have any agreement or understanding with the Buyer with respect to
the transactions contemplated by the Transaction Documents other than as specified in the Transaction Documents.

 

ii.                 
Registration Rights. No Person has any right to cause the Company or any Subsidiary to effect the registration under
the 1933 Act of any securities of the Company or any Subsidiary.

 

jj.                 
XBRL. The interactive data in extensible Business Reporting Language (“XBRL”) included or incorporated
by reference in the Registration Statement fairly presents the information called for in all material respects and has been prepared
in accordance with the SEC’s rules and guidelines applicable thereto.

 

kk.             
Disclosure. The Company confirms that neither it nor any other Person acting on its behalf has provided the Buyer
or its agents or counsel with any information that constitutes or could reasonably be expected to constitute material, non-public
information concerning the Company or any of its Subsidiaries, other than the existence of the transactions contemplated by this
Agreement and the other Transaction Documents. The Company understands and confirms that the Buyer will rely on the foregoing representations
in effecting transactions in securities of the Company. All disclosure provided to the Buyer regarding the Company and its Subsidiaries,
their businesses and the transactions contemplated hereby, including the schedules to this Agreement, furnished by or on behalf
of the Company or any of its Subsidiaries is true and correct and does not contain any untrue statement of a material fact or omit
to state any material fact necessary in order to make the statements made therein, in the light of the circumstances under which
they were made, not misleading. All of the written information furnished after the date hereof by or on behalf of the Company or
any of its Subsidiaries to the Buyer pursuant to or in connection with this Agreement and the other Transaction Documents, taken
as a whole, will be true and correct in all material respects as of the date on which such information is so provided and will
not contain any untrue statement of a material fact or omit to state any material fact necessary in order to make the statements
made therein, in the light of the circumstances under which they were made, not misleading. The press releases disseminated by
the Company during the twelve (12) months preceding the date of this Agreement, taken as a whole, are true and correct in all material
respects. No event or circumstance has occurred or information exists with respect to the Company or any of its Subsidiaries or
its or their business, properties, liabilities, prospects, operations (including results thereof) or conditions (financial or otherwise),
which, under applicable law, rule or regulation, requires public disclosure at or before the date hereof or announcement by the
Company but which has not been so publicly disclosed. The Company acknowledges and agrees that the Buyer
has not made any representations or warranties with respect to the transactions contemplated hereby other than those specifically
set forth in Section 2.

 

ll.                 
Accountants. RSM US LLP, whose report dated March 5, 2020 relating to the financial statements of the Company is
filed with the SEC as part of the Company’s Annual Report on Form 10-K for the year ended December 31, 2019 filed with the
Commission and incorporated by reference into the Registration Statement and the Prospectus, are and, during the periods covered
by their report, were an independent registered public accounting firm within the meaning of the 1933 Act and the Public Company
Accounting Oversight Board (United States).

 

    -23-

     

    

 

mm.         
 Listing and Maintenance Requirements. The Common Stock is registered pursuant to Section 12(b) of the 1934 Act,
and the Company has taken no action designed to, or which to its knowledge is likely to have the effect of, terminating the registration
of the Common Stock under the 1934 Act nor has the Company received any notification that the SEC is contemplating terminating
such registration. The Company is not in violation of any of the rules, regulations or requirements of the Principal Market and
has no knowledge of any facts or circumstances that could reasonably lead to delisting or suspension of the Common Stock by the
Principal Market in the foreseeable future. Except as disclosed in the SEC Documents, during the two years prior to the date hereof,
(i) the Common Stock has been listed or designated for quotation on the Principal Market, (ii) trading in the Common Stock has
not been suspended by the SEC or the Principal Market and (iii) the Company has received no communication, written or oral, from
the SEC or the Principal Market regarding the suspension or delisting of the Common Stock from the Principal Market. The Common
Stock is currently eligible for electronic transfer through the Depository Trust Company or another established clearing corporation
and the Company is current in payment of the fees to the Depository Trust Company (or such other established clearing corporation)
in connection with such electronic transfer.

 

nn.             
Public Float Calculation. As of the close of trading on the Principal Market on December 15, 2020, the aggregate
market value of the outstanding voting and non-voting common equity (as defined in Rule 405) of the Company held by persons other
than affiliates of the Company (pursuant to Rule 144, those that directly, or indirectly through one or more intermediaries, control,
or are controlled by, or are under common control with, the Company) (the “Non-Affiliate Shares”), was approximately
$21,588,812 (calculated by multiplying (x) the price at which the common equity of the Company was last sold on the Principal Market
December 15, 2020 by (y) the number of Non-Affiliate Shares outstanding on the date hereof.

 

oo.             
No Disqualification Events. With respect to the Warrants to be offered, issued and sold hereunder, in reliance on
Rule 506(b) of Regulation D, none of the Company, any of its predecessors, any affiliated issuer, any director,
executive officer, other officer of the Company participating in the offering hereunder, any beneficial owner of 20% or more of
the Company’s outstanding voting equity securities, calculated on the basis of voting power, nor any promoter (as that term
is defined in Rule 405 under the 1933 Act) connected with the Company in any capacity at the time of sale (each, an “Issuer
Covered Person”) is subject to any of the “Bad Actor” disqualifications described in Rule 506(d)(1)(i) to
(viii) of Regulation D (a “Disqualification Event”), except for a Disqualification Event covered by Rule 506(d)(2)
or (d)(3) of Regulation D. 

 

4.                 
COVENANTS.

 

a.                  
Reasonable Best Efforts. The Buyer shall use its reasonable best efforts to timely satisfy each of the covenants
hereunder and conditions to be satisfied by it as provided in Section 6 of this Agreement. The Company shall use its reasonable
best efforts to timely satisfy each of the covenants hereunder and conditions to be satisfied by it as provided in Section 7 of
this Agreement.

 

b.                  Form
D and Blue Sky. The Company agrees to file with the SEC a Form D with respect to the Warrant Securities as required under
Regulation D and to provide a copy thereof to the Buyer promptly after such filing. The Company shall, on or before the
Closing Date, take such action as the Company shall reasonably determine is necessary in order to obtain an exemption for, or
to, qualify the Securities for sale to, the Buyer at the Closing pursuant to this Agreement under applicable securities or
“Blue Sky” laws of the states of the United States (or to obtain an exemption from such qualification), and shall
provide evidence of any such action so taken to the Buyer on or prior to the Closing Date. The Company shall make any filings
and reports relating to the offer and sale of the Securities required under applicable securities or “Blue Sky”
laws of the states of the United States following the Closing Date.

 

    -24-

     

    

 

c.                  
Reporting Status. Until the earlier of (i) the date on which the Buyer shall have sold all of the Securities and
(ii) none of the Warrants remain outstanding (the “Reporting Period”), the Company shall timely file all reports
required to be filed with the SEC pursuant to the 1934 Act, and the Company shall not terminate its status as an issuer required
to file reports under the 1934 Act even if the 1934 Act or the rules and regulations thereunder would no longer require or otherwise
permit such termination.

 

d.                 
Use of Proceeds. The Company will use the proceeds from the sale of the Securities as described in the Prospectus
Supplement, but not, directly or indirectly, for (i) the satisfaction of any indebtedness of the Company or any of its Subsidiaries,
(ii) the redemption or repurchase of any securities of the Company or any of its Subsidiaries, or (iii) the settlement of any outstanding
litigation.

 

e.                  
Financial Information. The Company agrees to send the following to the Buyer during the Reporting Period (i) unless
the following are filed with the SEC through EDGAR and are available to the public through the EDGAR system, within one (1) Business
Day after the filing thereof with the SEC, a copy of its Annual Reports on Form 10-K and Quarterly Reports on Form 10-Q, any interim
reports or any consolidated balance sheets, income statements, stockholders’ equity statements and/or cash flow statements
for any period other than annual, any Current Reports on Form 8-K and any registration statements (other than on Form S-8) or amendments
filed pursuant to the 1933 Act, (ii) unless the following are either filed with the SEC through EDGAR or are otherwise widely disseminated
via a recognized news release service (such as PR Newswire), on the same day as the release thereof, facsimile copies of all press
releases issued by the Company or any of its Subsidiaries and (iii) unless the following are filed with the SEC through EDGAR,
copies of any notices and other information made available or given to the stockholders of the Company generally, contemporaneously
with the making available or giving thereof to the stockholders.

 

f.                    Listing.
The Company shall promptly secure the listing or designation for quotation (as the case may be) of all of the Underlying
Securities (as defined below) upon each national securities exchange and automated quotation system, if any, upon which the
Common Stock is then listed or designated for quotation (as the case may be) (subject to official notice of issuance) and
shall use commercially reasonable efforts to maintain such listing or designation for quotation (as the case may be) of all
Underlying Securities on such national securities exchange or automated quotation system. The Company shall use commercially
reasonable efforts to maintain the Common Stock’s listing or authorization for quotation (as the case may be) on the
Principal Market, The New York Stock Exchange, the NYSE American, The Nasdaq Global Market or The Nasdaq Global Select Market
(each, an “Eligible Market”). Neither the Company nor any of its Subsidiaries shall take any action which
could be reasonably expected to result in the delisting or suspension of the Common Stock (including, without limitation, the
Underlying Securities) on an Eligible Market. The Company shall pay all fees and expenses in connection with satisfying its
obligations under this Section 4(f). “Underlying Securities” means the (i) the Common Shares, (ii) the
Series B preferred Shares, (iii) the Warrant Shares, and (iv) any capital stock of the Company issued or issuable with
respect to the Common Shares, the Series B Stock, the Series B Preferred Shares, the Warrants, or the Warrant Shares,
including, without limitation, (1) as a result of any stock split, stock dividend, recapitalization, exchange or similar
event or otherwise and (2) shares of capital stock of the Company into which the shares of Common Stock are converted or
exchanged and shares of capital stock of a Successor Entity (as defined in the Warrants) into which the shares of Common
Stock are converted or exchanged, in each case, without regard to any limitations on conversion of the Series B Stock or
exercise of the Warrants.

 

    -25-

     

    

 

g.                 
Fees. The Company shall be responsible for the payment of any transfer agent fees, DTC fees or other fees relating
to or arising out of the transactions contemplated by the Transaction Documents. The Company shall pay, and hold the Buyer harmless
against, any liability, loss or expense (including, without limitation, reasonable attorneys’ fees and out-of- pocket expenses)
arising in connection with any claim relating to any such payment. Except as otherwise set forth in the Transaction Documents,
each party to this Agreement shall bear its own expenses in connection with the sale of the Securities to the Buyer.

 

h.                 
Pledge of Securities. Notwithstanding anything to the contrary contained in this Agreement, the Company acknowledges
and agrees that the Securities may be pledged by the Buyer in connection with a bona fide margin agreement or other loan or financing
arrangement that is secured by the Securities. The pledge of Securities shall not be deemed to be a transfer, sale or assignment
of the Securities hereunder, and no investor effecting a pledge of Securities shall be required to provide the Company with any
notice thereof or otherwise make any delivery to the Company pursuant to this Agreement or any other Transaction Document. The
Company hereby agrees to execute and deliver such documentation as a pledgee of the Securities may reasonably
request in connection with a pledge of the Securities to such pledgee by the Buyer.

 

i.                   
Prohibition of Short Sales and Hedging Transactions. During the term of this Agreement, the Buyer and its agents,
representatives and affiliates shall not in any manner whatsoever enter into or effect, directly or indirectly, any (i) “short
sale” (as such term is defined in Rule 200 of Regulation SHO of the 1934 Act) of the Common Stock or (ii) hedging transaction,
which establishes a net short position with respect to the Common Stock.

 

    -26-

     

    

 

j.                   
Disclosure of Transactions and Other Material Information.

 

i.                    Disclosure
of Transaction. The Company shall, on or before 9:00 a.m., New York time, on (i) the first (1st) Business Day after the
date of this Agreement, issue a press release (the “Press Release”) reasonably acceptable to the Buyer
disclosing all the material terms of the transactions contemplated by the Transaction Documents, and (ii) the second (2nd)
Business Day after the date of this Agreement, file with the SEC a Current Report on Form 8-K reasonably acceptable to the
Buyer describing all the material terms of the transactions contemplated by the Transaction Documents in the form required by
the 1934 Act and attaching all the material Transaction Documents (including, without limitation, this Agreement, the
Certificate of Designation of the Series B Stock and the form Warrant) (including all attachments, the “8-K
Filing”), and file with the SEC the Prospectus Supplement pursuant to Rule 424(b) under the 1933 Act specifically
relating to the transactions contemplated by, and describing the material terms and conditions of, the Transaction Documents,
containing information previously omitted at the time of effectiveness of the Registration Statement in reliance on Rule 430B
under the 1933 Act, and disclosing all information relating to the transactions contemplated hereby required to be disclosed
in the Registration Statement and the Prospectus as of the date of the Prospectus Supplement, including, without limitation,
information required to be disclosed in the section captioned “Plan of Distribution” in the Prospectus. The
Company shall permit the Buyer to review and comment upon the Press Release, the 8-K Filing and the Prospectus Supplement
within a reasonable time prior to their filing with the SEC, the Company shall give reasonable consideration to all such
comments, and the Company shall not issue the Press Release or file the 8-K or the Prospectus Supplement with the SEC in a
form to which either Buyer reasonably objects. The Buyer shall furnish to the Company such information regarding itself, the
Securities beneficially owned by it and the intended method of distribution thereof, including any arrangement
between each Buyer and any other Person relating to the sale or distribution of the Securities, as shall be reasonably
requested by the Company in connection with the preparation and issuance of the Press Release and the preparation and filing
of the 8-K and the Prospectus Supplement, and shall otherwise cooperate with the Company as reasonably requested by the
Company in connection with the preparation and issuance of the Press Release and the preparation and filing of the 8-K and
the Prospectus Supplement with the SEC. From and after the issuance of the Press Release, the 8-K Filing and the Prospectus
Supplement, the Company shall have disclosed all material, non- public information (if any) provided to the Buyer by the
Company or any of its Subsidiaries or any of its respective officers, directors, employees or agents in connection with the
transactions contemplated by the Transaction Documents. In addition, effective upon the issuance of the Press Release, the
Company acknowledges and agrees that any and all confidentiality or similar obligations under any agreement, whether written
or oral, between the Company, any of its Subsidiaries or any of their respective officers, directors, affiliates, employees
or agents, on the one hand, and any of the Buyer or any of their affiliates, on the other hand, shall terminate.

 

ii.                  Limitations
on Disclosure. The Company shall not, and the Company shall cause each of its Subsidiaries and each of its and their
respective officers, directors, employees and agents not to, provide the Buyer with any material, non-public information
regarding the Company or any of its Subsidiaries from and after the issuance of the Press Release without the express prior
written consent of the Buyer (which may be granted or withheld in the Buyer’s sole discretion). To the extent that the
Company delivers any material, non-public information to any of the Buyer without the Buyer’s consent, the Company
hereby covenants and agrees that such Buyer shall not have any duty of confidentiality with respect to, or a duty to the
Company not to trade on the basis of, such material, non-public information. Subject to the foregoing, neither the Company
nor any of its Subsidiaries shall issue any press releases or any other public statements with respect to the transactions
contemplated hereby; provided, however, the Company shall be entitled, without the prior approval of the Buyer, to issue any
press release or other public disclosure with respect to such transactions (i) in substantial conformity with the 8-K Filing
and contemporaneously therewith and (ii) as is required by applicable law and regulations (provided that in the case of
clause (i), the Buyer shall be consulted by the Company in connection with any such press release or other public disclosure
prior to its release). Without the prior written consent of the Buyer (which may be granted or withheld in the Buyer’s
sole discretion), the Company shall not (and shall cause each of its Subsidiaries and affiliates to not) disclose the name of
the Buyer in any filing, announcement, release or otherwise; provided, however, the Company shall be entitled, without the
prior approval of the Buyer, to issue any press release or other public disclosure with respect to such transactions (i) in
substantial conformity with the 8-K Filing and contemporaneously therewith and (ii) as is required by applicable law and
regulations (provided that in the case of clause (i), the Buyer shall be consulted by the Company in connection with any such
press release or other public disclosure prior to its release). Notwithstanding anything contained in this Agreement to the
contrary and without implication that the contrary would otherwise be true, the Company expressly
acknowledges and agrees that the Buyer shall not have (unless expressly agreed to by the Buyer after the date hereof in a
written definitive and binding agreement executed by the Company and the Buyer) any duty of confidentiality with respect to,
or a duty not to trade on the basis of, any material, non-public information regarding the Company or any of its
Subsidiaries.

 

    -27-

     

    

 

k.                 
Additional Issuance of Securities. So long as the Buyer beneficially owns any Securities, the Company will not, without
the prior written consent of the Buyer (which may be granted or withheld in the Buyer’s sole discretion), issue any other
securities that would cause a breach or default under any of the Series B Stock or Warrants.

 

l.                   
Reservation of Shares. So long as any portion of any of the Series B Stock or Warrants remains outstanding, the Company
shall take all action necessary to at all times have authorized, and reserved for the purpose of issuance, no less than 100% of
the sum of the maximum number of Series B Preferred Shares and Warrant Shares issuable upon conversion of the Series B Stock and
exercise in full of the Warrants, respectively (without regard to any limitations on the conversion of the Series B Stock and exercise
of the Warrants set forth therein) (collectively, the “Required Reserve Amount”). If at any time the number
of shares of Common Stock authorized and reserved for issuance is not sufficient to meet the Required Reserve Amount, the Company
will promptly take all corporate action necessary to authorize and reserve a sufficient number of shares, including, without limitation,
calling a special meeting of stockholders to authorize additional shares to meet the Company’s obligations pursuant to the
Transaction Documents, in the case of an insufficient number of authorized shares, obtain stockholder approval of an increase in
such authorized number of shares, and voting the management shares of the Company in favor of an increase in the authorized shares
of the Company to ensure that the number of authorized shares is sufficient to meet the Required Reserve Amount.

 

m.               
Conduct of Business. The business of the Company and its Subsidiaries shall not be conducted in violation of any
law, ordinance or regulation of any Governmental Entity, except where such violations would not reasonably be expected to result,
either individually or in the aggregate, in a Material Adverse Effect.

 

n.                  Passive
Foreign Investment Company. The Company shall conduct its business, and shall cause its Subsidiaries to conduct their
respective businesses, in such a manner as will ensure that the Company will not be deemed to constitute a passive foreign
investment company within the meaning of Section 1297 of the Code.

 

    -28-

     

    

 

o.                 
Corporate Existence. So long as any Buyer beneficially owns any Warrants, the Company shall not be party to any Fundamental
Transaction (as defined in the Warrants) unless the Company is in compliance with the applicable provisions governing Fundamental
Transactions set forth therein.

 

p.                 
Exercise and Conversion Procedures. The form of Exercise Notice (as defined in the Warrants) included in the Warrants
sets forth the totality of the procedures required of the Buyer in order to exercise the Warrants. No legal opinion or other information
or instructions shall be required of the Buyer to exercise any portion of the Warrants. The Company shall honor exercises of the
Warrants and shall deliver the applicable number of Warrant Shares in accordance with the terms, conditions and time periods set
forth in the Warrants. Without limiting the preceding sentences, no ink-original Exercise Notice shall be required, nor shall any
medallion guarantee (or other type of guarantee or notarization) of any Exercise Notice form be required in order to exercise any
portion of any of the Warrants. The form of Conversion Notice (as defined in the Certificate of Designations of the Series B Stock)
included in the Certificate of Designation of the Series B Stock sets forth the totality of the procedures required of the Buyer
in order to convert the Series B Stock. No legal opinion or other information or instructions shall be required of the Buyer to
convert any portion of the Series B Stock. The Company shall honor conversions of the Series B Stock and shall deliver the applicable
number of Series B Preferred Shares in accordance with the terms, conditions and time periods set forth in the Series B Stock.
Without limiting the preceding sentences, no ink-original Conversion Notice shall be required, nor shall any medallion guarantee
(or other type of guarantee or notarization) of any Conversion Notice form be required in order to exercise any portion of any
of the Series B Stock.

 

q.                 
Regulation M. The Company will not take any action prohibited by Regulation M under the 1934 Act, in connection with
the distribution of the Securities contemplated hereby.

 

r.                   
Passive Foreign Investment Company. The Company shall conduct its business in such a manner as will ensure that the
Company will not be deemed to constitute a passive foreign investment company within the meaning of Section 1297 of the Code.

 

s.                  
General Solicitation. None of the Company, any of its affiliates (as defined in Rule 501(b) under the 1933 Act) or
any person acting on behalf of the Company or such affiliate will solicit any offer to buy or offer or sell the Warrant Securities
by means of any form of general solicitation or general advertising within the meaning of Regulation D, including: (i) any advertisement,
article, notice or other communication published in any newspaper, magazine or similar medium or broadcast over television or radio;
and (ii) any seminar or meeting whose attendees have been invited by any general solicitation or general
advertising.

 

t.                    Integration.
None of the Company, its Subsidiaries, their affiliates nor any Person acting on their behalf will take any action or steps
that would (i) require registration of the offer, issuance or sale of the Warrant Securities under the 1933 Act, (ii) cause
the offer, issuance or sale of the Common Shares or Series B Stock to the Buyer hereunder pursuant to the Registration
Statement to be integrated with any other offering of securities of the Company (including, without limitation, the offer,
issuance or sale of the Warrant Securities, any prior or other offering of securities of the Company or otherwise), or (iii)
cause the offer, issuance or sale of the Warrant Securities to be integrated with any other offering of securities of the
Company (including, without limitation, the offer, issuance or sale of the Common Shares and Series B Stock to the Buyer
hereunder pursuant to the Registration Statement, any prior or other offering of securities of the Company or otherwise).

 

    -29-

     

    

 

 

u.                 
Notice of Disqualification Events. The Company will notify the Buyer in writing, prior to the Closing Date of (i)
any Disqualification Event relating to any Issuer Covered Person and (ii) any event that would, with the passage of time, reasonably
be expected to become a Disqualification Event relating to any Issuer Covered Person, in each case of which it is aware.

 

5.                 
REGISTER; TRANSFER AGENT INSTRUCTIONS; LEGEND.

 

a.                  
Register. The Company shall maintain at its principal executive offices (or such other office or agency of the Company
as it may designate by notice to each holder of Securities), a register for the Common Shares, the Series B Stock and the Warrants
being sold to the Buyer in which the Company shall record the name and address of the Person in whose name the Common Shares, the
Series B Stock and the Warrants have been issued (including the name and address of each transferee). The Company shall keep the
register open and available at all times during business hours for inspection of the Buyer or its legal representatives.

 

b.                 
Registration. The Company shall use commercially reasonable efforts to file with the SEC a registration statement
on Form S-1, S-3 or any other appropriate form in the sole discretion of the Company (the “Resale Registration Statement”),
registering for resale on a continuous or delayed basis in accordance with Rule 415(a)(i) of the 1933 Act the Warrant Shares issued
to the Buyer, and the Company shall use its commercially reasonable efforts to cause the Resale Registration Statement to become
effective as promptly as practicable following the date the Resale Registration Statement is initially filed with the SEC. The
Company shall cause the Resale Registration Statement to remain effective through and until such time as the Warrant Shares may
be available for resale by the Buyer pursuant to Rule 144 or its other subsections (or any successor thereto) under the 1933 Act.
The Company shall bear the expenses incurred in connection with the filing of the Resale Registration
Statement and all reasonable costs associated with the resale of the Warrant Shares (pursuant to the Resale Registration Statement
or otherwise).

 

c.                  
Legends. Certificates and any other instruments evidencing the Common Shares and the Series B Preferred Stock shall
not bear any restrictive or other legend. The Buyer understands that the Warrants are being issued pursuant to an exemption from
registration or qualification under the 1933 Act and applicable state securities laws, and except as set forth below, the Warrant
Securities shall bear any legend as required by the “blue sky” laws of any state and a restrictive legend in substantially
the following form (and a stop-transfer order may be placed against transfer of such stock certificates):

 

THE
SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR
APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED (I) IN THE
ABSENCE OF (A) AN EFFECTIVE REGISTRATION STATEMENT FOR THE SECURITIES UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR (B) AN
OPINION OF COUNSEL TO THE HOLDER (IF REQUESTED BY THE COMPANY), IN A FORM REASONABLY ACCEPTABLE TO THE COMPANY, THAT
REGISTRATION IS NOT REQUIRED UNDER SAID ACT OR (II) UNLESS SOLD OR ELIGIBLE TO BE SOLD PURSUANT TO RULE 144 OR RULE 144A
UNDER SAID ACT. NOTWITHSTANDING THE FOREGOING, THE SECURITIES MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN ACCOUNT OR
OTHER LOAN OR FINANCING ARRANGEMENT SECURED BY THE SECURITIES.

 

    -30- 

     

    

 

d.                 
Removal of Legends

 

Certificates
evidencing the Warrant Shares shall not be required to contain the legend set forth in Section 5(c) above or any other legend (i)
while a registration statement covering the resale of such Warrant Shares is effective under the 1933 Act, (ii) following any sale
of such Warrant Shares pursuant to Rule 144 (assuming the transferor is not an affiliate of the Company), (iii) if such Warrant
Shares are eligible to be sold, assigned or transferred under Rule 144 (provided that the Buyer provides the Company and/or the
Transfer Agent with reasonable assurances that such Warrant Shares are eligible for sale, assignment or transfer under Rule 144
(which may include an opinion of counsel, if so requested)), (iv) in connection with a sale, assignment or other transfer (other
than under Rule 144), provided that the Buyer provides the Company and/or the Transfer Agent with an opinion of counsel to the
Buyer, in a generally acceptable form, to the effect that such sale, assignment or transfer of the Warrant Shares may be made without
registration under the applicable requirements of the 1933 Act or (v) if such legend is not required under applicable requirements
of the 1933 Act (including, without limitation, controlling judicial interpretations and pronouncements issued by the SEC). If
a legend is not required pursuant to the foregoing, the Company shall no later than two (2) Trading Days following the delivery
by the Buyer to the Company or the Transfer Agent (with notice to the Company) of a legended certificate representing such Warrant
Shares (endorsed or with stock powers attached, signatures guaranteed, and otherwise in form necessary to affect the reissuance
and/or transfer, if applicable), together with any other deliveries from the Buyer as may be required above in this Section 5(d)
or reasonably requested by the Company and/or the Transfer Agent, as directed by the Buyer, either: (A) provided that the Transfer
Agent is participating in the DTC Fast Automated Securities Transfer Program, credit the aggregate number of Warrant Shares to
which the Buyer shall be entitled to the Buyer’s or its designee’s balance account with DTC through its Deposit/Withdrawal
at Custodian system or (B) if the Transfer Agent is not participating in the DTC Fast Automated Securities Transfer Program, issue
and deliver (via reputable overnight courier) to the Buyer, a certificate representing such Warrant Shares that is free from all
restrictive and other legends, registered in the name of the Buyer or its designee (the date by which such credit is so required
to be made to the balance account of the Buyer’s or the Buyer’s nominee with DTC or such certificate is required to
be delivered to the Buyer pursuant to the foregoing is referred to herein as the “Required Delivery Date”).

 

    -31- 

     

    

 

e.                  
 Buy-In. If the Company fails to so properly deliver such unlegended certificates representing the aggregate number
of Warrant Shares to which the Buyer shall be entitled, or so properly credit the aggregate number of Warrant Shares to which the
Buyer shall be entitled to the Buyer’s or its designee’s balance account with DTC through its Deposit/Withdrawal at
Custodian system, in each case by the Required Delivery Date, then, in addition to all other remedies available to the Buyer, (i)
the Company shall, pay to the Buyer, in cash, as partial liquidated damages and not as a penalty, for each $1,000 Warrant Shares
(based on the VWAP of the Common Stock on the date such Warrant Shares are submitted to the Transfer Agent) delivered for removal
of the restrictive legend and subject to Section 5(d), $10 per Trading Day (increasing to $20 per Trading Day five (5) Trading
Days after such damages have begun to accrue) for each Trading Day after the Legend Removal Date until such certificate is delivered
without a legend or such credit to such balance account with DTC is made and (ii) if after the Legend Removal Date the Buyer purchases
(in an open market transaction or otherwise) shares of Common Stock to deliver in satisfaction of a sale by the Buyer of all or
any portion of the number of shares of Common Stock, or a sale of a number of shares of Common Stock equal to all or any portion
of the number of shares of Common Stock, that the Buyer anticipated receiving from the Company without any restrictive legend,
then an amount equal to the excess of the Buyer’s total purchase price (including brokerage commissions and other out-of-pocket
expenses, if any) for the shares of Common Stock so purchased (including brokerage commissions and other out-of-pocket expenses,
if any) over the product of (A) such number of Warrant Shares that the Company was required to deliver to the Buyer by the Legend
Removal Date multiplied by (B) the lowest closing sale price of the Common Stock on any Trading Day during the period commencing
on the date of the delivery by the Buyer to the Company of the applicable Warrant Shares (as the case may be) and ending on the
date of such delivery and payment under this Section 5(e).

 

f.                   
FAST Compliance. While any portion of any of the Warrants remain outstanding, the Company shall maintain a transfer
agent that participates in the DTC Fast Automated Securities Transfer Program.

 

6.                 
CONDITIONS TO THE COMPANY’S OBLIGATION TO SELL.

 

The
obligation of the Company hereunder to issue and sell the Common Shares, the Series B Stock and the Warrants to the Buyer at the
Closing is subject to the satisfaction, at or before the Closing Date, of each of the following conditions, provided that these
conditions are for the Company’s sole benefit and may be waived by the Company at any time in its sole discretion by providing
the Buyer with prior written notice thereof:

 

a.                  
The Buyer shall have executed this Agreement and delivered the same to the Company.

 

b.                 
The Buyer shall have delivered to the Company the Purchase Price for the Common Shares, the Series B Stock and the Warrants
being purchased by the Buyer at the Closing by wire transfer of immediately available funds in accordance with the Flow of Funds
Letter.

 

c.                   The
representations and warranties of the Buyer shall be true and correct in all material respects as of the date when made and
as of the Closing Date as though originally made at that time (except for representations and warranties that speak as of a
specific date, which shall be true and correct as of such specific date), and the Buyer shall have performed, satisfied and
complied in all material respects with the covenants, agreements and conditions required by this Agreement to be performed,
satisfied or complied with by the Buyer at or prior to the Closing Date.

 

    -32- 

     

    

 

7.                 
CONDITIONS TO THE BUYER’S OBLIGATION TO PURCHASE.

 

The
obligation of the Buyer hereunder to purchase the Common Shares, the Series B Stock and the Warrants at the Closing is subject
to the satisfaction, at or before the Closing Date, of each of the following conditions, provided that these conditions are for
the Buyer’s sole benefit and may be waived by the Buyer at any time in its sole discretion by providing the Company with
prior written notice thereof:

 

a.                  
The Company shall have duly executed and delivered to the Buyer each of the Transaction Documents, and the Company shall
have (A) caused the Transfer Agent to credit an aggregate 485,912 Common Shares to the Buyer’s or its designees’ balance
account with DTC through its Deposit/Withdrawal at Custodian system, (B) deliver to the Buyer an aggregate of 237,745 shares of
Series B Stock and (C) deliver to the Buyer the Warrants (initially for an aggregate of up to 669,854 Warrant Shares), duly executed
on behalf of the Company and registered in the name of the Buyer or its designee.

 

b.                 
The Buyer shall have received the opinion of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C., the Company’s counsel,
dated as of the Closing Date, in the form reasonably acceptable to the Buyer.

 

c.                  
The Company shall have delivered to the Buyer a certificate evidencing the formation and good standing of the Company and
each of its Subsidiaries in each such entity’s jurisdiction of formation issued by the Secretary of State (or comparable
office) of such jurisdiction of formation as of a date within ten (10) days of the Closing Date.

 

d.                 
The Company shall have delivered to the Buyer a certificate evidencing the Company’s qualification as a foreign corporation
and good standing issued by the Secretary of State (or comparable office) of each jurisdiction in which the Company conducts business
and is required to so qualify, as of a date within ten (10) days of the Closing Date.

 

e.                  
The Company shall have delivered to the Buyer a certificate, in the form acceptable to the Buyer, executed by the Secretary
of the Company and dated as of the Closing Date, as to (i) the resolutions consistent with Section 3(b) as adopted by the Company’s
board of directors (or a committee thereof) in a form reasonably acceptable to the Buyer, (ii) the Certificate of Incorporation
of the Company and (iii) the Bylaws of the Company, each as in effect at the Closing.

 

f.                    Each
and every representation and warranty of the Company shall be true and correct as of the date when made and as of the Closing
Date as though originally made at that time (except for representations and warranties that speak as of a specific date,
which shall be true and correct as of such specific date) and the Company shall have performed, satisfied and complied in all
respects with the covenants, agreements and conditions required to be performed, satisfied or complied with by the Company at
or prior to the Closing Date. The Buyer shall have received a certificate, duly executed by the Chief Executive Officer of
the Company, dated as of the Closing Date, to the foregoing effect and as to such other matters as may be reasonably
requested by the Buyer in the form acceptable to the Buyer.

 

    -33- 

     

    

 

g.                 
The Common Stock (A) shall be designated for quotation or listed (as applicable) on the Principal Market and (B) shall not
have been suspended, as of the Closing Date, by the SEC or the Principal Market from trading on the Principal Market nor shall
suspension by the SEC or the Principal Market have been threatened, as of the Closing Date, either (I) in writing by the SEC or
the Principal Market or (II) by falling below the minimum maintenance requirements of the Principal Market.

 

h.                 
The Company shall have obtained all governmental, regulatory or third party consents and approvals, if any, necessary for
the sale of the Securities, including without limitation, those required by the Principal Market, if any.

 

i.                   
No statute, rule, regulation, executive order, decree, ruling or injunction shall have been enacted, entered, promulgated
or endorsed by any court or Governmental Entity of competent jurisdiction that prohibits the consummation of any of the transactions
contemplated by the Transaction Documents.

 

j.                   
Since the date of execution of this Agreement, no event or series of events shall have occurred that reasonably would have
or result in a Material Adverse Effect.

 

k.                 
The Company shall have obtained approval of the Principal Market to list or designate for quotation (as the case may be)
the Common Shares, the Series B Preferred Shares and the Warrant Shares.

 

l.                   The
Buyer shall have received a letter on the letterhead of the Company, duly executed by the Chief Executive Officer of the Company,
setting forth the wire transfer instructions of the Company (the “Flow of Funds Letter”).

 

m.                
From the date hereof to the Closing Date, (i) trading in the Common Stock shall not have been suspended by the SEC or the
Principal Market (except for any suspension of trading of limited duration agreed to by the Company, which suspension shall be
terminated prior to the Closing), and, (ii) at any time prior to the Closing Date, trading in securities generally as reported
by Bloomberg L.P. shall not have been suspended or limited, or minimum prices shall not have been established on securities whose
trades are reported by such service, or on the Principal Market, nor shall a banking moratorium have been declared either by the
United States or New York State authorities nor shall there have occurred any material outbreak or escalation of hostilities or
other national or international calamity of such magnitude in its effect on, or any material adverse change in, any financial market
which, in each case, in the reasonable judgment of the Buyer, makes it impracticable or inadvisable to purchase the Securities
at the Closing.

 

n.                 
The Registration Statement shall be effective and available for the issuance and sale to the Buyer s hereunder of an aggregate
485,912 Common Shares and 237,745 shares of Series B Stock.

 

o.                 
The Company shall have delivered to the Buyer the Prospectus and the Prospectus Supplement (which may be delivered in accordance
with Rule 172 under the 1933 Act).

 

    -34- 

     

    

 

p.                 
 The Company shall reimburse the Buyer for its expenses in connection with this transaction in an amount up to $15,000.

 

q.                 
The Company and its Subsidiaries shall have delivered to the Buyer such other documents, instruments or certificates relating
to the transactions contemplated by this Agreement as the Buyer or its counsel may reasonably request.

 

8.                 
TERMINATION.

 

In
the event that the Closing shall not have occurred within five (5) days of the date hereof, then the Buyer shall have the right
to terminate its obligations under this Agreement at any time on or after the close of business on such date without liability
of the Buyer to the Company; provided, however, the right to terminate this Agreement under this Section 8 shall not be available
to the Buyer if the failure of the transactions contemplated by this Agreement to have been consummated by such date is the result
of the Buyer’s breach of this Agreement. Nothing contained in this Section 8 shall be deemed to release any party from any
liability for any breach by such party of the terms and provisions of this Agreement or the other Transaction Documents or to impair
the right of any party to compel specific performance by any other party of its obligations under this Agreement or the other Transaction
Documents.

 

9.                 
MISCELLANEOUS.

 

a.                  
Governing Law; Jurisdiction; Jury Trial. All questions concerning the construction, validity, enforcement and interpretation
of this Agreement shall be governed by the internal laws of the State of New York, without giving effect to any choice of law or
conflict of law provision or rule (whether of the State of New York or any other jurisdictions) that
would cause the application of the laws of any jurisdictions other than the State of New York. The Company hereby irrevocably submits
to the exclusive jurisdiction of the state and federal courts sitting in The City of New York, Borough of Manhattan, for the adjudication
of any dispute hereunder or in connection herewith or under any of the other Transaction Documents or with any transaction contemplated
hereby or thereby, and hereby irrevocably waives, and agrees not to assert in any suit, action or proceeding, any claim that it
is not personally subject to the jurisdiction of any such court, that such suit, action or proceeding is brought in an inconvenient
forum or that the venue of such suit, action or proceeding is improper. Each party hereby irrevocably waives personal service of
process and consents to process being served in any such suit, action or proceeding by mailing a copy thereof to such party at
the address for such notices to it under this Agreement and agrees that such service shall constitute good and sufficient service
of process and notice thereof. Nothing contained herein shall be deemed to limit in any way any right to serve process in any manner
permitted by law. Nothing contained herein shall be deemed or operate to preclude the Buyer from bringing suit or taking other
legal action against the Company in any other jurisdiction to collect on the Company’s obligations to the Buyer or to enforce
a judgment or other court ruling in favor of the Buyer. EACH PARTY HEREBY IRREVOCABLY WAIVES ANY RIGHT IT MAY HAVE TO, AND AGREES
NOT TO REQUEST, A JURY TRIAL FOR THE ADJUDICATION OF ANY DISPUTE HEREUNDER OR UNDER ANY OTHER TRANSACTION DOCUMENT OR IN CONNECTION
WITH OR ARISING OUT OF THIS AGREEMENT, ANY OTHER TRANSACTION DOCUMENT OR ANY TRANSACTION CONTEMPLATED HEREBY OR THEREBY.

 

    -35- 

     

    

 

b.                 
 Counterparts. This Agreement may be executed in two or more identical counterparts, all of which shall be considered
one and the same agreement and shall become effective when counterparts have been signed by each party and delivered to the other
party. In the event that any signature is delivered by facsimile transmission or by an e-mail which contains a portable document
format (.pdf) file of an executed signature page, such signature page shall create a valid and binding obligation of the party
executing (or on whose behalf such signature is executed) with the same force and effect as if such signature page were an original
thereof.

 

c.                  
Headings; Gender. The headings of this Agreement are for convenience of reference and shall not form part of, or
affect the interpretation of, this Agreement. Unless the context clearly indicates otherwise, each pronoun herein shall be deemed
to include the masculine, feminine, neuter, singular and plural forms thereof. The terms “including,” “includes,”
“include” and words of like import shall be construed broadly as if followed by the words “without limitation.”
The terms “herein,” “hereunder,” “hereof” and words of like import refer to this entire Agreement
instead of just the provision in which they are found.

 

d.                  Severability;
Maximum Payment Amounts. If any provision of this Agreement is prohibited by law or otherwise determined to be invalid or
unenforceable by a court of competent jurisdiction, the provision that would otherwise be prohibited, invalid or
unenforceable shall be deemed amended to apply to the broadest extent that it would be valid and enforceable, and the
invalidity or unenforceability of such provision shall not affect the validity of the remaining provisions of this Agreement
so long as this Agreement as so modified continues to express, without material change, the original intentions of the parties
as to the subject matter hereof and the prohibited nature, invalidity or unenforceability of the provision(s) in question
does not substantially impair the respective expectations or reciprocal obligations of the parties or the practical
realization of the benefits that would otherwise be conferred upon the parties. The parties will endeavor in good faith
negotiations to replace the prohibited, invalid or unenforceable provision(s) with a valid provision(s), the effect of which
comes as close as possible to that of the prohibited, invalid or unenforceable provision(s). Notwithstanding anything to the
contrary contained in this Agreement or any other Transaction Document (and without implication that the following is
required or applicable), it is the intention of the parties that in no event shall amounts and value paid by the Company
and/or any of its Subsidiaries (as the case may be), or payable to or received by any of the Buyer, under the Transaction
Documents (including without limitation, any amounts that would be characterized as “interest” under applicable
law) exceed amounts permitted under any applicable law. Accordingly, if any obligation to pay, payment made to the Buyer, or
collection by the Buyer pursuant the Transaction Documents is finally judicially determined to be contrary to any such
applicable law, such obligation to pay, payment or collection shall be deemed to have been made by mutual mistake of the
Buyer, the Company and its Subsidiaries and such amount shall be deemed to have been adjusted with retroactive effect to the
maximum amount or rate of interest, as the case may be, as would not be so prohibited by the applicable law. Such adjustment
shall be effected, to the extent necessary, by reducing or refunding, at the option of the Buyer, the amount of interest or
any other amounts which would constitute unlawful amounts required to be paid or actually paid to the Buyer under the
Transaction Documents. For greater certainty, to the extent that any interest, charges, fees, expenses or other amounts
required to be paid to or received by the Buyer under any of the Transaction Documents or related thereto are held to be
within the meaning of “interest” or another applicable term to otherwise be violative of applicable law, such
amounts shall be pro-rated over the period of time to which they relate.

 

    -36- 

     

    

 

e.                  
Entire Agreement; Amendments. This Agreement, the other Transaction Documents and the schedules and exhibits attached
hereto and thereto and the instruments referenced herein and therein supersede all other prior oral or written agreements between
the Buyer, the Company, its Subsidiaries, their affiliates and Persons acting on their behalf, and this Agreement, the other Transaction
Documents, the schedules and exhibits attached hereto and thereto and the instruments referenced herein and therein contain the
entire understanding of the parties solely with respect to the matters covered herein and therein. For clarification purposes,
the Recitals are part of this Agreement. Provisions of this Agreement may be amended only with the written consent of the Company
and the Buyer, and any amendment of any provision of this Agreement made in conformity with the provisions of this Section 9(e)
shall be binding upon the Buyer and the Company. No waiver shall be effective unless it is in writing
and signed by an authorized representative of the waiving party, and any waiver of any provision of this Agreement made in conformity
with the provisions of this Section 9(e) shall be binding on the waiving party. The Company has not, directly or indirectly, made
any agreements with the Buyer relating to the terms or conditions of the transactions contemplated by the Transaction Documents
except as set forth in the Transaction Documents. Without limiting the foregoing, the Company confirms that, except as set forth
in this Agreement, the Buyer has not made any commitment or promise or has any other obligation to provide any financing to the
Company, any Subsidiary or otherwise. As a material inducement for the Buyer to enter into this Agreement, the Company expressly
acknowledges and agrees that (i) no due diligence or other investigation or inquiry conducted by the Buyer, any of its advisors
or any of its representatives shall affect the Buyer’s right to rely on, or shall modify or qualify in any manner or be an
exception to any of, the Company’s representations and warranties contained in this Agreement or any other Transaction Document,
(ii) nothing contained in the Registration Statement, the Prospectus or the Prospectus Supplement shall affect the Buyer’s
right to rely on, or shall modify or qualify in any manner or be an exception to any of, the Company’s representations and
warranties contained in this Agreement or any other Transaction Document and (iii) unless a provision of this Agreement or any
other Transaction Document is expressly preceded by the phrase “except as disclosed in the SEC Documents,” nothing
contained in any of the SEC Documents shall affect the Buyer’s right to rely on, or shall modify or qualify in any manner
or be an exception to any of, the Company’s representations and warranties contained in this Agreement or any other Transaction
Document.

 

f.                   
Notices. Any notices, consents, waivers or other communications required or permitted to be given under the terms
of this Agreement must be in writing and will be deemed to have been delivered: (i) upon receipt, when delivered personally; (ii)
upon receipt, when sent by facsimile (provided confirmation of transmission is mechanically or electronically generated and kept
on file by the sending party) or electronic mail; or (iii) one (1) Business Day after deposit with an overnight courier service
with next day delivery specified, in each case, properly addressed to the party to receive the same. The addresses, facsimile numbers
and e-mail addresses for such communications shall be:

 

    -37- 

     

    

 

If
to the Company:

 

Cyclacel Pharmaceuticals,
Inc.

200 Connell
Drive, Suite 1500

Berkeley Heights,
New Jersey 07922

e-mail: pmcbarron@cyclacel.com

Attention: Paul McBarron, Chief Operating Officer,
Chief Financial Officer, and Executive Vice President, Finance

 

With
a copy (for informational purposes only) to:

 

Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.

666 Third Avenue

New York, NY 10017

e-mail: JIPapernik@mintz.com

Attention: Joel I. Papernik

 

If to the Transfer Agent:

 

American Stock Transfer & Trust Company

6201 15th Avenue

Brooklyn, NY 11219

Atention: Jennifer A. Donovan

 

If to the Buyer:

Acorn Bioventures, L.P.

Attention: Anders Hove

420 Lexington Avenue, Suite 2626

New
York, NY 10170

Email: anders@acornca.com

Phone: 212-299-4777

 

With a copy (for
informational purposes only) to:

 

Goodwin Procter LLP

601 Marshall Street

Redwood City, CA 94063

Attention: Heidi Mayon

Email: hmayon@goodwinlaw.com

Phone: 650-752-3227

 

or to such other address, e-mail
address and/or facsimile number and/or to the attention of such other Person as the recipient party has specified by written
notice given to each other party five (5) days prior to the effectiveness of such change. Written confirmation of receipt (A)
given by the recipient of such notice, consent, waiver or other communication, (B) mechanically or electronically generated
by the sender’s facsimile machine or e-mail containing the time, date, recipient facsimile number and, with respect to
each facsimile transmission, an image of the first page of such transmission or (C) provided by an overnight courier service
shall be rebuttable evidence of personal service, receipt by facsimile or receipt from an overnight courier service in
accordance with clause (i), (ii) or (iii) above, respectively.

 

    -38- 

     

    

 

g.                 
Successors and Assigns. This Agreement shall be binding upon and inure to the benefit of the parties and their respective
successors and assigns, including any subsequent purchasers of any of the Series B Stock and Warrants (but excluding any purchasers
of Underlying Securities, unless pursuant to a written assignment by the Buyer). The Company shall not assign this Agreement or
any rights or obligations hereunder without the prior written consent of the Buyer, including, without limitation, by way of a
Fundamental Transaction (as defined in the Warrants) (unless the Company is in compliance with the applicable provisions governing
Fundamental Transactions set forth in the Warrants). The Buyer may assign some or all of its rights hereunder in connection with
any transfer of any of its Securities without the consent of the Company, in which event such assignee shall be deemed to be the
Buyer hereunder with respect to such assigned rights.

 

h.                 
No Third Party Beneficiaries. This Agreement is intended for the benefit of the parties hereto and their respective
permitted successors and assigns, and is not for the benefit of, nor may any provision hereof be enforced by, any other Person,
other than the Indemnitees referred to in Section 9(k).

 

i.                   
Survival. The representations, warranties, agreements and covenants shall survive the Closing.

 

j.                   
Further Assurances. Each party shall do and perform, or cause to be done and performed, all such further acts and
things, and shall execute and deliver all such other agreements, certificates, instruments and documents, as any other party may
reasonably request in order to carry out the intent and accomplish the purposes of this Agreement and the consummation of the transactions
contemplated hereby.

 

    -39- 

     

    

 

k.                 
Indemnification.

 

i.                    In
consideration of the Buyer’s execution and delivery of this Agreement and acquiring the Securities and in addition to
all of the Company’s other obligations under the Transaction Documents, the Company shall defend, protect, indemnify
and hold harmless the Buyer and each holder of any Securities and all of their stockholders, partners, members, officers,
directors, employees and direct or indirect investors and any of the foregoing Persons’ agents or other representatives
(including, without limitation, those retained in connection with the transactions contemplated by
this Agreement) (collectively, the “Indemnitees”) from and against any and all actions, causes of action,
suits, claims, losses, costs, penalties, fees, liabilities and damages, and expenses in connection therewith (irrespective of
whether any such Indemnitee is a party to the action for which indemnification hereunder is sought), and including reasonable
attorneys’ fees and disbursements (the “Indemnified Liabilities”), incurred by any Indemnitee as a
result of, or arising out of, or relating to (i) any misrepresentation or breach of any representation or warranty made by
the Company in any of the Transaction Documents, (ii) any breach of any covenant, agreement or obligation of the Company
contained in any of the Transaction Documents, (iii) any cause of action, suit, proceeding or claim brought or made against
such Indemnitee by a third party (including for these purposes a derivative action brought on behalf of the Company or any
Subsidiary) or which otherwise involves such Indemnitee that arises out of or results from (A) the execution, delivery,
performance or enforcement of any of the Transaction Documents, (B) any transaction financed or to be financed in whole or in
part, directly or indirectly, with the proceeds of the issuance of the Securities, (C) the status of the Buyer or holder of
the Securities either as an investor in the Company pursuant to the transactions contemplated by the Transaction Documents or
as a party to this Agreement (including, without limitation, as a party in interest or otherwise in any action or proceeding
for injunctive or other equitable relief), or (D) with respect to any registration statement of the Company providing for the
resale by the Buyer of any Series B Stock and Warrant Shares issued and issuable upon conversion of the Series B Stock and
exercise of the Warrants, respectively, filed by the Company with the SEC, (1) any untrue or alleged untrue statement of a
material fact contained in such registration statement, any prospectus or any form of prospectus or in any amendment or
supplement thereto or in any preliminary prospectus, or arising out of or relating to any omission or alleged omission of a
material fact required to be stated therein or necessary to make the statements therein (in the case of any prospectus or
supplement thereto, in light of the circumstances under which they were made) not misleading, except to the extent, but only
to the extent, that such untrue statements or omissions are based solely upon information regarding the Buyer furnished in
writing to the Company by the Buyer expressly for use therein or (2) any violation or alleged violation by the Company of the
1933 Act, the 1934 Act or any state securities law, or any rule or regulation thereunder in connection therewith. To the
extent that the foregoing undertaking by the Company may be unenforceable for any reason, the Company shall make the maximum
contribution to the payment and satisfaction of each of the Indemnified Liabilities which is permissible under applicable
law.

 

ii.                  Promptly
after receipt by an Indemnitee under this Section 9(k) of notice of the commencement of any action or proceeding (including
any governmental action or proceeding) involving an Indemnified Liability, such Indemnitee shall, if a claim in respect
thereof is to be made against the Company under this Section 9(k), deliver to the Company a written notice of the
commencement thereof, and the Company shall have the right to participate in, and, to the extent the Company so desires, to
assume control of the defense thereof with counsel mutually satisfactory to the Company and the Indemnitee; provided,
however, that an Indemnitee shall have the right to retain its own counsel with the fees and expenses of such counsel to be
paid by the Company if: (A) the Company has agreed in writing to pay such fees and expenses; (B) the Company shall have
failed promptly to assume the defense of such Indemnified Liability and to employ counsel reasonably satisfactory to such
Indemnitee in any such Indemnified Liability; or (C) the named parties to any such Indemnified Liability (including any
impleaded parties) include both such Indemnitee and the Company, and such Indemnitee shall have been advised by counsel that
a conflict of interest is likely to exist if the same counsel were to represent such Indemnitee
and the Company (in which case, if such Indemnitee notifies the Company in writing that it elects to employ separate counsel
at the expense of the Company, then the Company shall not have the right to assume the defense thereof and such counsel shall
be at the expense of the Company), provided further, that in the case of clause (C) above the Company shall not be
responsible for the reasonable fees and expenses of more than one (1) separate legal counsel for the Indemnitees. The
Indemnitee shall reasonably cooperate with the Company in connection with any negotiation or defense of any such action or
Indemnified Liability by the Company and shall furnish to the Company all information reasonably available to the Indemnitee
which relates to such action or Indemnified Liability. The Company shall keep the Indemnitee reasonably apprised at all times
as to the status of the defense or any settlement negotiations with respect thereto. The Company shall not be liable for any
settlement of any action, claim or proceeding effected without its prior written consent, provided, however, that the Company
shall not unreasonably withhold, delay or condition its consent. The Company shall not, without the prior written consent of
the Indemnitee, consent to entry of any judgment or enter into any settlement or other compromise which does not include as
an unconditional term thereof the giving by the claimant or plaintiff to such Indemnitee of a release from all liability in
respect to such Indemnified Liability or litigation, and such settlement shall not include any admission as to fault on the
part of the Indemnitee. Following indemnification as provided for hereunder, the Company shall be subrogated to all rights of
the Indemnitee with respect to all third parties, firms or corporations relating to the matter for which indemnification has
been made. The failure to deliver written notice to the Company within a reasonable time of the commencement of any such
action shall not relieve the Company of any liability to the Indemnitee under this Section 9(k), except to the extent that
the Company is materially and adversely prejudiced in its ability to defend such action.

 

    -40- 

     

    

 

iii.               
The indemnification required by this Section 9(k) shall be made by periodic payments of the amount thereof during the course
of the investigation or defense, within ten (10) days after bills are received or Indemnified Liabilities are incurred.

 

iv.               
The indemnity agreement contained herein shall be in addition to (A) any cause of action or similar right of the Indemnitee
against the Company or others, and (B) any liabilities the Company may be subject to pursuant to the law.

 

l.                   
Construction. The language used in this Agreement will be deemed to be the language chosen by the parties to express
their mutual intent, and no rules of strict construction will be applied against any party. No specific representation or warranty
shall limit the generality or applicability of a more general representation or warranty. Each and every reference to share prices,
shares of Common Stock and any other numbers in this Agreement that relate to the Common Stock shall be automatically adjusted
for any stock splits, stock dividends, stock combinations, recapitalizations or other similar transactions that occur with respect
to the Common Stock after the date of this Agreement. It is expressly understood and agreed that for all purposes of this Agreement,
and without implication that the contrary would otherwise be true, neither transactions nor purchases nor sales shall include the
location and/or reservation of borrowable shares of Common Stock.

 

m.                Remedies.
The Buyer and in the event of assignment by Buyer of its rights and obligations hereunder, each holder of any Securities,
shall have all rights and remedies set forth in the Transaction Documents and all rights and
remedies which such holders have been granted at any time under any other agreement or contract and all of the rights which
such holders have under any law. Any Person having any rights under any provision of this Agreement shall be entitled to
enforce such rights specifically (without posting a bond or other security), to recover damages by reason of any breach of
any provision of this Agreement and to exercise all other rights granted by law. Furthermore, the Company recognizes that in
the event that it or any Subsidiary fails to perform, observe, or discharge any or all of its or such Subsidiary’s (as
the case may be) obligations under the Transaction Documents, any remedy at law would inadequate relief to the Buyer. The
Company therefore agrees that the Buyer shall be entitled to specific performance and/or temporary, preliminary and permanent
injunctive or other equitable relief from any court of competent jurisdiction in any such case without the necessity of
proving actual damages and without posting a bond or other security. The remedies provided in this Agreement and the other
Transaction Documents shall be cumulative and in addition to all other remedies available under this Agreement and the other
Transaction Documents, at law or in equity (including a decree of specific performance and/or other injunctive
relief).

 

    -41- 

     

    

 

n.                 
Withdrawal Right. Notwithstanding anything to the contrary contained in (and without limiting any similar provisions
of) the Transaction Documents, whenever the Buyer exercises a right, election, demand or option under a Transaction Document and
the Company or any Subsidiary does not timely perform its related obligations within the periods therein provided, then the Buyer
may rescind or withdraw, in its sole discretion from time to time upon written notice to the Company or such Subsidiary (as the
case may be), any relevant notice, demand or election in whole or in part without prejudice to its future actions and rights; provided,
however, that in the case of a rescission of a conversion of Series B Stock or an exercise of the Warrants, the Buyer shall be
required to return any Series B Preferred Shares or Warrant Shares, respectively, subject to any such rescinded exercise notice
concurrently with the return to the Buyer of the aggregate exercise price paid to the Company for such Series B Preferred Shares
or Warrant Shares and the restoration of the Buyer’s right to acquire such Series B Preferred Shares or Warrant Shares pursuant
to such Series B Stock or Warrants (including, issuance of a replacement warrant certificate evidencing such restored right), respectively.

 

o.                 
Payment Set Aside; Currency. To the extent that the Company makes a payment or payments to the Buyer hereunder or
pursuant to any of the other Transaction Documents or the Buyer enforce or exercise their rights hereunder or thereunder, and such
payment or payments or the proceeds of such enforcement or exercise or any part thereof are subsequently invalidated, declared
to be fraudulent or preferential, set aside, recovered from, disgorged by or are required to be refunded, repaid or otherwise restored
to the Company, a trustee, receiver or any other Person under any law (including, without limitation, any bankruptcy law, foreign,
state or federal law, common law or equitable cause of action), then to the extent of any such restoration the obligation or part
thereof originally intended to be satisfied shall be revived and continued in full force and effect as if such payment had not
been made or such enforcement or setoff had not occurred. Unless otherwise expressly indicated, all dollar amounts referred to
in this Agreement and the other Transaction Documents are in United States Dollars (“U.S. Dollars”), and all
amounts owing under this Agreement and all other Transaction Documents shall be paid in U.S. Dollars. All amounts denominated in
other currencies (if any) shall be converted into the U.S. Dollar equivalent amount in accordance with the Exchange Rate on the
date of calculation. “Exchange Rate” means, in relation to any amount of currency
to be converted into U.S. Dollars pursuant to this Agreement, the U.S. Dollar exchange rate as published in the Wall Street Journal
on the relevant date of calculation.

 

    -42- 

     

    

 

p.                  Judgment
Currency. If for the purpose of obtaining or enforcing judgment against the Company in connection with this Agreement or
any other Transaction Document in any court in any jurisdiction it becomes necessary to convert into any other currency (such
other currency being hereinafter in this Section 9(p) referred to as the “Judgment Currency”) an amount
due in U.S. Dollars under this Agreement, the conversion shall be made at the Exchange Rate prevailing on the Trading Day
immediately preceding:

 

i.                  
the date actual payment of the amount due, in the case of any proceeding in the courts of New York or in the courts of any
other jurisdiction that will give effect to such conversion being made on such date: or

 

ii.                 
the date on which the foreign court determines, in the case of any proceeding in the courts of any other jurisdiction (the
date as of which such conversion is made pursuant to this Section 9(p)(ii) being hereinafter referred to as the “Judgment
Conversion Date”).

 

1.                 
If in the case of any proceeding in the court of any jurisdiction referred to in Section 9(p)(ii) above, there is a change
in the Exchange Rate prevailing between the Judgment Conversion Date and the date of actual payment of the amount due, the applicable
party shall pay such adjusted amount as may be necessary to ensure that the amount paid in the Judgment Currency, when converted
at the Exchange Rate prevailing on the date of payment, will produce the amount of U.S. Dollars which could have been purchased
with the amount of Judgment Currency stipulated in the judgment or judicial order at the Exchange Rate prevailing on the Judgment
Conversion Date.

 

2.                 
Any amount due from the Company under this provision shall be due as a separate debt and shall not be affected by judgment
being obtained for any other amounts due under or in respect of this Agreement or any other Transaction Document.

 

q.                 
Liquidated Damages. The Company’s obligations to pay any partial liquidated damages or other amounts owing
under the Transaction Documents is a continuing obligation of the Company and shall not terminate until all unpaid partial liquidated
damages and other amounts have been paid notwithstanding the fact that the instrument or security pursuant to which such partial
liquidated damages or other amounts are due and payable shall have been canceled.

 

[signature
pages follow]

 

    -43- 

     

    

 

IN WITNESS WHEREOF, this
Securities Purchase Agreement is executed as of the Effective Date.

 

	Number of shares of Common Stock Subscribed For: 485,912	 
	Number of shares of Series B Stock Subscribed For: 237,745	 
	Number of Warrants Subscribed For: 669,854	 
	Total Purchase Price: $6,999,982.65	 
	Signature of Authorized Signatory:	 
	Address of Subscriber:	 
	Subscriber’s tax ID#:	 
	Subscriber’s Email Address: 	 
	 	 
	ACCEPTED BY:	 
	 	 
	
        CYCLACEL PHARMACEUTICALS, INC.,

        a Delaware corporation
	 
	 	 
	Signature of Authorized Signatory:	                                                                                                                                         
	Name of Authorized Signatory:	                                                                                                                                          
	Title of Authorized Signatory:	                                                                                                                                         

 

    -44-banf-ex101_33.htm

Exhibit 10.1

 

 

AMENDED AND RESTATED

BANCFIRST CORPORATION STOCK OPTION PLAN

 

	
1.
	
PURPOSE.  This Amended and Restated BancFirst Corporation Stock Option Plan (“the Plan”) incorporates the amendments to the Sixteenth Amended and Restated BancFirst Corporation Stock Option Plan adopted by the stockholders of BancFirst Corporation (the “Company”) on December 22, 2020.  

 

The Plan is intended to incent long-term employment with the Company, and encourage ownership of Company Common Stock by certain key employees and officers of the Company and its subsidiaries, in order to increase their proprietary interest in the Company's success.

 

The Plan is intended to comply with Section 409A of the Code.

 

	
2.
	
DEFINITIONS.  As used herein, the following terms shall have the corresponding meanings:

 

	
 
	
2.1.
	
“Board of Directors” shall mean the Board of Directors of the Company.

 

	
 
	
2.2.
	
“Charity” shall mean any organization that has been recognized by the Internal Revenue Service as qualifying under Section 501(c)(3) of the Code of 1986.

 

	
 
	
2.3.
	
“Code” shall mean the U.S. Internal Revenue Code of 1986, as amended.

 

	
 
	
2.4
	
“Committee” shall mean the Board of Directors or the Executive Committee acting under authority delegated by the Board of Directors.

 

	
 
	
2.5.
	
“Common Stock” shall mean the common stock, par value $1.00 per share, of the Company.

 

	
 
	
2.6.
	
“Continuous Service” shall mean, with respect to any Employee, the absence of any interruption or termination of service as an Employee.  Such status shall not be considered interrupted in the case of (a) sick leave, (b), military leave, (c), except as otherwise provided in any leave policy adopted by the Company or one of its Subsidiaries from time to time, an approved leave of absence or (d) a transfer between locations and/or between the Company and its Subsidiaries.  The determination whether an Employee remains in Continuous Service shall be made by the Committee, in its sole discretion.  

 

	
 
	
2.7.
	
“Date of Grant” shall mean the date of the approval by the Committee of a Stock Option granted hereunder as set forth in the applicable stock option award agreement.  In the event of a grant conditioned, among other things, upon stockholder ratification of this Plan, the date of such conditional grant shall be the Date of Grant for purposes of this Plan.

 

	
 
	
2.8.
	
“Employee” shall mean any person employed by the Company or any Subsidiary of the Company.

 

	
 
	
2.9.
	
“Executive Committee” shall mean the Executive Committee of the Board of Directors.

 

	
 
	
2.10.
	
“Fair Market Value” shall mean, with respect to the grant of a Stock Option under the Plan, (a) if the Common Stock is listed on a national securities exchange or NASDAQ, the closing price of the Common Stock for the business day of the Date of Grant, or (b) if the Common Stock is not then listed on an exchange, the average of the closing bid and asked prices per share for the Common Stock in the over-the-counter market as quoted on such market for the business day of the Date of Grant or (c) if the Common Stock is not then listed on any exchange or quoted on an over-the-counter market, an amount determined in good faith by the Committee to be the fair market value of the Common Stock, after consideration of all relevant factors, on the Date of Grant.  In all events, “Fair Market Value” shall be determined in good faith by the Committee in a manner that will 

1

 

	
 
		
comply with the provisions of Section 409A of the Code and the regulations promulgated thereunder.

 

	
 
	
2.11.
	
“NASDAQ” shall mean NASDAQ Global Market, Inc.

 

	
 
	
2.12.
	
“Nonqualified Stock Option” shall mean a Stock Option that is not intended to qualify for tax treatment as an “incentive stock option” under Section 422 of the Code.

 

	
 
	
2.13.
	
“Option Exercise Price” shall mean the price paid for shares of Common Stock upon the exercise of a Stock Option granted hereunder.

 

	
 
	
2.14.
	
“Optionee” shall mean any person entitled to exercise a Stock Option pursuant to the terms of the Plan.

 

	
 
	
2.15.
	
“Stock Option” shall mean a stock option giving an Optionee the right to purchase shares of the Company’s Common Stock.  Stock Options granted under the Plan shall be Nonqualified Stock Options.

 

	
 
	
2.16.
	
“Subsidiary” shall mean a subsidiary company, whether now or hereafter existing, of the Company.

 

3.ADMINISTRATION.  

 

	
 
	
3.1
	
AUTHORITY.  The Plan shall be administered by, and all Stock Options shall be authorized by, the Committee.  

 

	
 
	

	
Subject to the provisions of the Plan and subject to the approval of any relevant authority, including, without limitation, the required approval, if any, of any national securities exchange or NASDAQ, the Committee shall have the following authority, in its discretion:

 

	
 
	
(a)
	
to determine the Option Exercise Price, which shall be equal to the Fair Market Value of the Common Stock in accordance with the definition of such term contained herein;

 

	
 
	
(b)
	
to select the Employees to whom Stock Options may from time to time be granted hereunder;

 

	
 
	
(c)
	
to determine whether and to what extent Stock Options are granted hereunder;

 

	
 
	
(d)
	
to determine the number of shares of Common Stock covered by each Stock Option granted hereunder;

 

	
 
	
(e)
	
to approve forms of agreement for use under the Plan;

 

	
 
	
(f)
	
to determine when and under what circumstances a Stock Option exercise may be settled in cash or other consideration instead of Common Stock;

 

	
 
	
(g) 
	
to construe and to interpret the terms and the conditions of the Plan and the Stock Options granted pursuant to the Plan; and

 

	
 
	
(h)
	
to adopt and to revise any regulations and rules as the Committee may deem necessary or advisable to administer the Plan.

 

	
 
	

	
Notwithstanding anything else contained herein, except for (a) an adjustment pursuant to Section 12, or (b) the cancellation and re-grant of Stock Options that re-establishes the Fair Market Value of the Common Stock and therefore the Option Exercise Price of Stock Options not to exceed a total of 300,000 shares in any period of twelve (12) continuous months, which the Committee may affect 

2

 

	
 
		
without stockholder approval,  in no case may the Committee amend an outstanding Stock Option to reduce the Option Exercise Price of the Stock Option.

 

	
 
	
3.2.
	
EFFECT OF DECISIONS.  All constructions, decisions, determinations and interpretations of the Committee shall be final and binding upon all persons having an interest in the Plan and/or any Stock Option.  

 

	
 
	
3.3.
	
EXCULPATION; INDEMNIFICATION. No member of the Committee shall be liable for any action made in good faith, and the members shall be entitled to indemnification and reimbursement in the manner provided in the Company's Certificate of Incorporation, or as otherwise permitted by law.  A member of the Committee shall be eligible to receive a grant of a Stock Option under the Plan on the same terms as other Employees.  However, if the Committee grants Stock Options to a member of the Committee, such grant shall not be effective until such grant is approved by the Compensation Committee of the Board of Directors, consisting of three (3) or more "independent directors" as defined in and determined pursuant to the Marketplace Rules of the NASDAQ or any stock exchange upon which the Common Stock of the Company is listed.  

 

	
 
	
3.4.
	
RULE 16B-3 COMPLIANCE.  With respect Optionees who are subject to Section 16(b) of the Exchange Act, the Plan shall be administered in compliance with the requirements of Rule 16b-3.  

 

	
4.
	
ELIGIBILITY.  The individuals that shall be eligible to participate in the Plan shall be such key Employees (including officers) of the Company and/or one of its Subsidiaires in which the Company has proprietary interest by reason of stock ownership or otherwise, including any company in which the Company acquires a proprietary interest after the adoption of this Plan (but only if the Company owns, directly or indirectly,  not less than 50% of the total combined voting power in the company), as the Committee shall determine from time to time.  

 

	
5.
	
STOCK.  The stock subject to Stock Options and the other provisions of the Plan shall be shares of the Company’s authorized but unissued Common Stock or treasury stock, as determined by the Committee.  Subject to adjustment in accordance with Section 6.9 and Section 6.10, the total number of shares of Common Stock of the Company on which Stock Options may be granted under the Plan subsequent to the effective date of this amended and restated Plan shall not exceed in the aggregate 320,000 shares.  In the event that any outstanding Stock Option under the Plan for any reason expires or is terminated prior to the end of the period during which Stock Options may be granted, the shares of the Common Stock allocable to the unexercised portion of such Stock Option may again be subject to a Stock Option under the Plan.

 

	
6.
	
TERMS AND CONDITIONS OF STOCK OPTIONS.  Stock Options granted pursuant to the Plan shall be evidenced by a stock option award agreement in such form as the Committee shall, from time to time, approve.  Stock Options shall comply with and be subject to the following terms and conditions:

 

	
 
	
6.1.
	
MEDIUM AND TIME OF PAYMENT.  The Option Exercise Price shall be payable in United States Dollars upon the exercise of the Stock Option and may be paid in cash or by certified check, bank draft or money order payable to the order of the Company, unless otherwise determined by the Committee. The consideration to be paid for shares of Common Stock to be issued upon exercise of a Stock Option, including, without limitation, the method of payment may be determined by the Committee and may consist entirely of (a) cash or certified check, bank draft or money order payable to the order of the Company, (b), to the extent permitted by applicable law, regulation or rule, authorization for the Company to retain from the total number of shares of Common Stock for which the Stock Option is exercised that number of shares of Common Stock having a Fair Market Value on the date of exercise equal to the exercise price for the total number of shares of Common Stock for which the Stock Option is exercised or (c) a combination of the foregoing.

 

	
 
	
6.2.
	
NUMBER OF SHARES.  The Stock Option shall state the total number of shares to which it pertains. 

 

3

 

	
 
	
6.3.
	
OPTION EXERCISE PRICE.  The Option Exercise Price shall be not less than the Fair Market Value of the Common Stock on the Date of Grant.

 

	
 
	
6.4.
	
TERM OF STOCK OPTIONS.  The period during which Stock Options shall be exercisable shall be fixed by the Committee, but in no event shall a Stock Option be exercisable after the expiration of fifteen (15) years from the date such Stock Option is granted.  Subject to the foregoing, Stock Options shall be exercisable at such times and be subject to such restrictions and conditions as the Committee shall in each instance determine, which restrictions and conditions need not be the same for all Stock Options.

 

	
 
	
6.5.
	
PROCEDURE FOR EXERCISE.  Any Stock Option shall be exercisable at such times, on such terms and subject to such conditions as may be determined by the Committee and reflected in the stock option agreement.

 

	
 
	

	
A Stock Option shall be deemed to be exercised when notice of such exercise has been given to the Company by the person entitled to exercise the Stock Option and the Company has received full payment of the Option Exercise Price in accordance with Section 6.1.  

 

	
 
	
6.6.
	
DATE OF EXERCISE.  Unless otherwise determined by the Committee at the time of granting a Stock Option or in accordance with this Plan, Stock Options shall be exercisable at the rate set forth below beginning four (4) years from the Date of Grant.  After becoming exercisable, the Stock Option may be exercised at any time and from time to time in whole or in part (but in whole share increments) until termination of the Stock Option as set forth this Plan.

 

	
Elapsed Years from

Date of Grant
	
 
	
Percent

of Shares
	
 
	
 
	
 
	
Cumulative

Percent

of Shares
	
 

	
less than 4 years
	
 
	
0
	
%
	
 
	
 
	
0
	
%

	
4 but less than 5 years
	
 
	
25
	
%
	
 
	
 
	
25
	
%

	
5 but less than 6 years
	
 
	
25
	
%
	
 
	
 
	
50
	
%

	
6 but less than 7 years
	
 
	
25
	
%
	
 
	
 
	
75
	
%

	
7 or more years
	
 
	
25
	
%
	
 
	
 
	
100
	
%

 

	
 
	
6.7.
	
TERMINATION OF EMPLOYMENT.  In the event of the termination of an Optionee’s Continuous Employment as an Employee, such Optionee’s Stock Option, whether or not then exercisable, shall terminate immediately; provided, however, that if the termination is not as a result of embezzlement, theft or other violation of the law, the Optionee shall have the right to exercise such Stock Option (to the extent exercisable at the time of termination) at any time within thirty (30) days after such termination; provided, further, that if any termination of employment is related to the Optionee's retirement with the consent of the Company or one of its Subsidiaries, or the Optionee’s disability, the Optionee shall have the right to exercise such Stock Option (to the extent exercisable up to the date of retirement) at any time within six (6) months after such retirement; and provided, further, that if the Optionee dies while in the employment of the Company or within the period of time after termination of employment or retirement during which such Optionee was entitled to exercise such Stock Optionee as hereinabove provided, his estate, personal representative or beneficiary shall have the right to exercise such Stock Option (to the extent exercisable at the date of death) at any time within twelve (12) months from the date of such Optionee death or disability.

 

	
 
	
6.8.
	
REINSTATEMENT.  Notwithstanding anything contained in Section 6, the Committee has the authority to reinstate a Stock Option forfeited under Section 6.7 if the Optionee resumes employment as an Employee within twelve (12) months following such termination; provided, however, in no event shall any such reinstatement extend the specified expiration date of the Stock Option.

 

4

 

	
 
	
6.9.
	
RECAPITALIZATION.  The aggregate number of shares of Common Stock on which Stock Options may be granted to persons participating under the Plan, the number of shares thereof covered by each outstanding Stock Option, and the price per share thereof in each such Stock Option, shall all be proportionately adjusted for any increase or decrease in the number of issued shares of Common Stock of the Company resulting from a subdivision or consolidation of shares or other capital adjustment or the payment of a stock dividend or other increase or decrease in such shares, effected without receipt of consideration by the Company; provided, however, that any fractional shares resulting from such adjustment shall be eliminated.  In the event of a change in the Company's Common Stock that is limited to a change in the designation thereof to “Capital Stock” or other similar designation, or a change in the par value thereof, or from par value to no par value, without increase in the number of issued shares, the shares resulting from any such change shall be deemed to be Common Stock within the meaning of the Plan. 

 

	
 
	
6.10.
	
REORGANIZATION OF COMPANY.  Subject to any required action by the stockholders of the Company, if the Company shall be the surviving or resulting corporation in any merger or consolidation that does not result in change of control of the Company, any Stock Option granted hereunder shall pertain and apply to the securities to which a holder of the number of shares of Common Stock subject to the Stock Option would have been entitled.  In the event of a dissolution or liquidation of the Company or a merger or consolidation in which the Company is not the surviving or resulting corporation or that results in a change in control of the Company, or a tender or exchange offer which results in a change in control of the Company, the Committee shall determine: (a) whether all or any part of the unexercisable portion of any Stock Option outstanding under the Plan shall terminate; (b) whether the Stock Options shall become immediately exercisable; or (c) whether such Stock Options may be exchanged for options covering securities of any such surviving or resulting corporation, subject to the agreement of any such surviving or resulting corporation, on terms and conditions substantially similar to a Stock Option hereunder.

 

	
 
	
6.11.
	
TAX WITHHOLDING.  Upon any event that requires tax withholding in connection with any Stock Option, the Company or one of its Subsidiaries shall have the right at its option:

 

	
 
	
(a)
	
to require the Optionee (or the estate, personal representative or beneficiary) to pay or to provide for the payment of any taxes that the Company or one of its Subsidiaries may be required to withhold with respect to such event; or

 

	
 
	
(b)
	
to deduct from any amount otherwise payable in cash to the Optionee (or the estate, personal representative or beneficiary) the amount of any taxes that the Company or one of its Subsidiaries may be required to withhold with respect to such event.

 

	
 
	

	
In any case where tax is required to be withheld in connection with the delivery of securities under the Plan, the Committee may in its sole discretion (subject to applicable laws, regulations and rules) require or grant the Optionee (or the estate, personal representative or beneficiary) the right to elect, pursuant to such regulations and such rules as may be established by the Committee  and subject to such conditions as may be established by the Committee, that the Company reduce the number of shares of Common Stock to be delivered by (or otherwise reacquire from the such person) the appropriate number of shares of Common Stock, valued at a consistent manner with the Fair Market Value or at the sales price in accordance with cashless exercises, necessary to satisfy the applicable withholding obligation.   

 

	
 
	
6.12.
	
ASSIGNABILITY.  Except as provided in this Section 6.12, no Stock Option shall be assignable or transferable except as follows:

 

	
 
	
(a)
	
by will or by the laws of descent and distribution.

 

	
 
	
(b)
	
for the purpose of making a charitable gift as permitted by Section 6.16.

 

5

 

	
 
	
(c)
	
to the Optionee as trustee or to the Optionee and one or more others as co-trustees, of a revocable trust that allows the Optionee to amend or revoke the trust at any time.  If the Optionee relinquishes such Optionee’s power to amend or revoke the trust or resigns as a trustee, the Optionee shall withdraw the Stock Option from the trust prior to the relinquishment of such power or such Optionee’s resignation as trustee and shall re-vest title to the Stock Option in the Optionee’s individual name.  If the trust becomes irrevocable due to the death of the Optionee, the successor or remaining trustee(s) shall have the same power to exercise the Stock Option under Section 6.7 as the personal representative.  If the Optionee becomes incapacitated, the date of incapacity shall be deemed for purposes of this Plan as the date of termination of employment under Section 6.6 (whether or not Optionee’s employment has actually terminated), and the successor or remaining trustee(s) of the trust shall have the same right to exercise the Stock Option as a terminated Optionee has under Section 6.7.  The Optionee as trustee and any successor or remaining trustee(s) shall be bound by all the terms and conditions of the Plan and the stock option award agreement delivered by the Company to the Optionee under this Plan.

 

	
 
	
(d)
	
to the extent set forth in the stock option aware agreement governing such Stock Option.

 

	
 
	
6.13.
	
OPTIONEE'S AGREEMENT.  If, at the time of the exercise of any Stock Option, it is necessary or desirable, in order to comply with any applicable laws, rules or regulations relating to the sale of securities, that the Optionee exercising the Stock Option shall agree that such Optionee will purchase the shares that are subject to the Stock Option for investment and not with any present intention to resell the same, the Optionee will, upon the request of the Company, execute and deliver to the Company an agreement to such effect.

 

	
 
	
6.14.
	
RIGHTS AS A STOCKHOLDER.  An Optionee shall have no rights as a stockholder with respect to shares covered by his Stock Option until the date of issuance of the shares to him and only after such shares are fully paid.

 

	
 
	
6.15.
	
OTHER PROVISIONS.  The stock option award agreement authorized under the Plan may contain such other provisions as the Committee shall deem advisable.

 

	
 
	
6.16.
	
Charitable Gift.  An Optionee shall be permitted to assign such Optionee’s Stock Option without consideration, either in full or in one or more partial assignments from time to time, to a Charity.  Assignment(s) may be made during the Optionee’s lifetime or may be effective upon his death.  If a Stock Option is assigned to a Charity, in whole or in part, it shall continue to be subject to Section 6.6 and Section 6.6, which shall thereafter apply to the same extent as if the Stock Option were still held by the Optionee himself (if the Optionee is living), or by the Optionee’s estate, personal representative or beneficiary (if the Optionee is deceased).

 

	
7.
	
MARKETABILITY OF SHARES.  The Common Stock is currently traded on NASDAQ.  As a result, its liquidity varies widely in response to supply and demand.  Consequently, the Company can give no assurances as to the marketability of shares acquired under the Plan.

 

	
8.
	
TAX IMPLICATIONS.  It is anticipated that Stock Options granted under the Plan will be treated as Nonqualified Stock Options by the Internal Revenue Service.  As such, exercise of the Stock Option would generate a taxable event with the difference between the original Option Exercise Price and the Fair Market Value of the Common Stock at the time of exercise being treated as ordinary income.  If a Stock Option is transferred to a Charity as permitted by Section 6.12(b) and Section 6.16, the Optionee should expect to have ordinary income attributed to him at the time the Charity exercises the Stock Option, in the same amount and with the same effect as if the Optionee exercised the Stock Option.

 

	
9.
	
TERM OF PLAN.  No Stock Option may be granted after December 31, 2024.

 

	
10.
	
NO OBLIGATION TO EXERCISE OPTION.  The granting of a Stock Option shall impose no obligation upon the Optionee to exercise such Stock Option.

6

 

 

	
11.
	
COMPLIANCE WITH LAW.  The Plan, the granting and the vesting of Stock Options, the offer, the issuance and the delivery of shares of Common Stock and/or the payment of money under the Plan are subject to compliance with all applicable federal and state laws, regulations and rules (including, without limitation, federal and state securities laws, regulations and rules and federal margin requirements) and to such approval by governmental, listing or regulatory authorities as may be necessary or advisable in connection therewith.   Any person acquiring any securities under the Plan shall, if requested by the Company or one of its Subsidiaries, provide such assurances and representations as  the Committee may deem necessary or advisable to assure compliance with all applicable legal and accounting requirements.

 

	
12.
	
AMENDMENTS.  

 

	
 
	
12.1
	
AMENDMENT AND TERMINATION.  The Committee may alter, amend, discontinue, suspend or terminate the Plan or any portion thereof at any time, including any alteration, discontinuance, suspension or termination necessary to comply with any tax, securities or regulatory law or requirement or any applicable listing requirement with which the Committee intends the Plan to comply; provided, however, no such alteration, discontinuance, suspension or termination shall be made without shareholder approval if such amendment constitutes a “material amendment.” For purposes of the Plan, a “material amendment” shall mean an amendment that (a) materially increases the benefits accruing to Optionees in the Plan, (b) materially increases the number of securities that may be issued under the Plan, (c) materially modifies the requirements for participation in the Plan or (d) is otherwise deemed a material amendment by the Committee pursuant to any applicable law, regulation or rule, applicable accounting or listing standards.

 

	
 
	
12.2
	
AMENDMENTS TO OPTIONS.  The Committee may not amend the terms and conditions of a Stock Option without the prior written consent of the Optionee.

 

	
 
	
12.3
	
LIMITATIONS ON AMENDMENTS TO THE PLAN. No alteration, amendment, suspension or termination of the Plan or change affecting any outstanding Stock Option shall, without the prior written consent of the Optionee, affect in a manner materially adverse to such Optionee, the obligations of the Optionee under any Stock Option granted prior to the effective date of such change.   Changes under Section 6.9 and Section 6.10 shall not be deemed to materially adverse changes under this Section 12.3.

 

 

7

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00318-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00318-of-00352.parquet"}]]